Regeneron Pharmaceuticals, Inc. v. Amgen Inc.

1:22-cv-00697 | Delaware District Court

Interested in this case?

Request a Demo Track this case, and find millions of cases like it, let us show you how.
Division Wilmington
Judge Judge Jennifer L. Hall
Filed May 27, 2022
Case Flags MOTREF and Multi-Media Docs
Nature of Suit 410 Anti-Trust
Cause 15:1 Antitrust Litigation
Jury Demand Plaintiff
Related Case 1:14-cv-01317
Last Updated: 1 day, 11 hours ago Show Interactive Timeline
Upcoming Events
1 Day
  • 4/22/2025
SO ORDERED, re 416 Stipulation and Order Extending Time for the Parties to File Public Redacted Versions of D.I. 414 and D.I. 415 to April 22, 2025.
Redaction Request due 4/22/2025.
Source
Add
3+ Days
  • 4/24/2025
  • 4/25/2025
ORAL ORDER: IT IS HEREBY ORDERED that the Pretrial Conference scheduled for April 25, 2025 is RESCHEDULED for April 24, 2025 at 1:00 PM in Courtroom 6D before Judge Jennifer L. Hall.
Source
Add
4 Days
  • 4/25/2025
ORAL ORDER: IT IS HEREBY ORDERED that a Pretrial Conference is set for April 25, 2025 at 1:00 p.m. in Courtroom 6D.
Source
Add
11 Days
  • 5/2/2025
Redacted Transcript Deadline set for 5/2/2025.
ORAL ORDER: It is HEREBY ORDERED that Magistrate Judge Laura D. Hatcher will conduct jury selection on May 2, 2025 in Courtroom 6D at 9:00 AM.
Letter to The Honorable Jennifer L. Hall from David E. Wilks regarding the parties consent to a Magistrate Judge presiding over the jury selection process on May 2, 2025..
The Court requests that the parties consent to jury selection by a U.S. Magistrate Judge on May 2, 2025.
Source
Add
10 Weeks
  • 6/30/2025
Release of Transcript Restriction set for 6/30/2025.
Source
Add
Filing Date # Docket Text
4/17/2025Jury Instructions - Proposed
4/17/2025Jury Instructions - Proposed
4/17/2025Verdict Sheet - Proposed
4/17/2025Verdict Sheet - Proposed
4/17/2025Voir Dire - Proposed
4/17/2025Jury Instructions - Proposed
4/17/2025
  • Motion
Proposed Pretrial Order
4/14/2025Notice of Service
4/14/2025Notice of Service
4/14/2025Notice of Service
4/14/2025Notice of Service
4/10/2025422
  • Order
ORAL ORDER: IT IS HEREBY ORDERED that the Pretrial Conference scheduled for April 25, 2025 is RESCHEDULED for April 24, 2025 at 1:00 PM in Courtroom 6D before Judge Jennifer L. Hall. Ordered by Judge Jennifer L. Hall on 4/10/2025. (twk) (Entered: 04/10/2025)
4/10/2025421
  • OrderGranted
ORAL ORDER: IT IS HEREBY ORDERED that Regeneron's Motion to Supplement the Expert Report of its Damages Expert (D.I. 411 ) is GRANTED-IN-PART and DENIED-IN-PART as announced from the bench at the April 9, 2025 hearing. Ordered by Judge Jennifer L. Hall on 4/10/2025. (twk) (Entered: 04/10/2025)
4/10/2025
  • Daubert Motion
ORDER REGARDING DAUBERT MOTIONS. (*See Order for details). Signed by Judge Jennifer L. Hall on 4/10/2025. (ceg) . (Entered: 04/10/2025)
4/10/2025
  • Motion for Summary JudgmentDenied
ORDER: IT IS HEREBY ORDERED that Amgen's Motion for Summary Judgment (D.I. 307 ) is DENIED. (*See Order for details). Signed by Judge Jennifer L. Hall on 4/10/2025. (ceg) (Entered: 04/10/2025)
4/9/2025Minute Entry for proceedings held before Judge Jennifer L. Hall - Telephone Conference held on 4/9/2025. (Court Reporter: H. Triozzi.) (twk) (Entered: 04/09/2025)
4/8/2025418
  • Order
ORAL ORDER Setting Teleconference: A teleconference is scheduled for April 9, 2025 at 1:00 PM before Judge Jennifer L. Hall. The parties shall call the Court's conference line at (855) 244-8681, access code 2307 149 6568. Ordered by Judge Jennifer L. Hall on 4/8/2025. (twk) (Entered: 04/08/2025)
4/8/2025Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute Teleconference held on 4/8/2025. (Court Reporter: H. Triozzi.) (twk) (Entered: 04/08/2025)
4/8/2025SO ORDERED, re 416 Stipulation and Order Extending Time for the Parties to File Public Redacted Versions of D.I. 414 and D.I. 415 to April 22, 2025. Signed by Judge Jennifer L. Hall on 4/8/2025. (ceg) (Entered: 04/08/2025)
4/7/2025 STIPULATION and [Proposed] Order Extending Time for the Parties to File Public Redacted Versions re 415 Letter, 414 Letter by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 04/07/2025)
4/3/2025[SEALED] Letter to The Honorable Jennifer L. Hall from Melanie K. Sharp regarding Opposition to Regeneron's Motion for Leave to Rely on Supplemental Damages Expert Report - re 412 Order Setting Teleconference,,,,. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 04/03/2025)
4/1/2025[SEALED] Letter to The Honorable Jennifer L. Hall from David E. Wilks regarding Updated Damages Expert Report Dispute. (Attachments: # 1 Exhibit A-D, # 2 Certificate of Service)(Wilks, David) (Entered: 04/01/2025)
4/1/2025Official Transcript of Hearing held on 11-20-24 before Judge Hall. Court Reporter Stacy Ingram,Email: stacy_ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/22/2025. Redacted Transcript Deadline set for 5/2/2025. Release of Transcript Restriction set for 6/30/2025. (Ingram, Stacy) (Entered: 04/01/2025)
3/31/2025Pro Hac Vice Attorney Courtney L. Spears for Amgen Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (cdd) (Entered: 03/31/2025)
3/28/2025412
  • Order
ORAL ORDER Setting Teleconference: The Court has reviewed the Motion for Teleconference to Resolve Discovery Dispute (D.I. 411 ). A discovery dispute teleconference is scheduled for April 8, 2025 at 4:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than April 1, 2025, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than April 3, 2025, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Ordered by Judge Jennifer L. Hall on 3/28/2025. (ceg) (Entered: 03/28/2025)
3/26/2025
  • Motionby Π
MOTION for Teleconference to Resolve Discovery Dispute - filed by Regeneron Pharmaceuticals, Inc.. (Wilks, David) (Entered: 03/26/2025)
3/24/2025
  • Motion to Appear Pro Hac Vice
SO ORDERED, re 409 Motion for Pro Hac Vice Appearance of Attorney Courtney L. Spears filed by Amgen Inc. Ordered by Judge Jennifer L. Hall on 3/24/2025. (ceg) (Entered: 03/24/2025)
3/24/2025410Pro Hac Vice Fee - Credit Card Payment received for Courtney L. Spears. ( re 409 MOTION for Pro Hac Vice Appearance of Attorney Courtney L. Spears )( Payment of $ 50, receipt number ADEDC-4643778).(Vangellow, Stephanie) (Entered: 03/24/2025)
3/24/2025
  • Motion to Appear Pro Hac Viceby Δ
MOTION for Pro Hac Vice Appearance of Attorney Courtney L. Spears - filed by Amgen Inc.. (Attachments: # 1 Verification)(Vangellow, Stephanie) (Entered: 03/24/2025)
3/12/2025 NOTICE of Change of Firm Affiliation of Eric Hochstadt by Regeneron Pharmaceuticals, Inc. (Wilks, David) (Entered: 03/12/2025)
3/10/2025 NOTICE of Change of Firm Affiliation of Adam Banks and Jonathan Polkes by Regeneron Pharmaceuticals, Inc. (Czerwonka, Scott) (Entered: 03/10/2025)
1/22/2025406
  • Order
ORAL ORDER: It is HEREBY ORDERED that Magistrate Judge Laura D. Hatcher will conduct jury selection on May 2, 2025 in Courtroom 6D at 9:00 AM. Ordered by Judge Jennifer L. Hall on 1/22/2025. (ceg) (Entered: 01/22/2025)
1/15/2025 Letter to The Honorable Jennifer L. Hall from David E. Wilks regarding the parties consent to a Magistrate Judge presiding over the jury selection process on May 2, 2025.. (Wilks, David) (Entered: 01/15/2025)
1/8/2025404
  • Order
ORAL ORDER: IT IS HEREBY ORDERED that a Pretrial Conference is set for April 25, 2025 at 1:00 p.m. in Courtroom 6D. A 7-day jury trial is set for May 5-8 and 12-14, 2025, in courtroom 6D. The Court requests that the parties consent to jury selection by a U.S. Magistrate Judge on May 2, 2025. The parties shall submit a joint letter indicating whether or not they consent by January 15, 2025. Ordered by Judge Jennifer L. Hall on 1/8/2025. (ceg) (Entered: 01/08/2025)
11/27/2024Joint Letter to The Honorable Jennifer L. Hall from David E. Wilks regarding responses to questions during the November 20th hearing. (Wilks, David) (Entered: 11/27/2024)
11/25/2024402
  • Order
ORAL ORDER: For the reasons stated at the November 20, 2024 motion hearing, Plaintiff's Objections to the Magistrate Judge's Memorandum and Order (D.I. 387 ) are OVERRULED and the Memorandum and Order (D.I. 385 ) is ADOPTED. Ordered by Judge Jennifer L. Hall on 11/25/2024. (twk) (Entered: 11/25/2024)
11/20/2024Minute Entry for proceedings held before Judge Jennifer L. Hall - Motion Hearing held on 11/20/2024. (Court Reporter S. Ingram.) (twk) (Entered: 11/21/2024)
11/19/2024
  • Order
SO ORDERED, re 400 Plaintiff Regeneron Pharmaceuticals, Inc.'s Motion for Exemption of Persons from the District Court of Delaware's May 2024 Standing Order on Personal Devices for purposes of the summary judgment and Daubert motions hearing scheduled for November 20, 2024. Signed by Judge Jennifer L. Hall on 11/19/2024. (ceg) (Entered: 11/19/2024)
11/19/2024
  • Motionby Π
MOTION for Exemption of Persons from the District Court of Delaware's May 2024 Standing Order on Personal Devices - filed by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 11/19/2024)
11/19/2024
  • Order
SO ORDERED, re 398 Defendant Amgen Inc.'s Motion for Exemption of Persons from the District Court of Delaware's May 2024 Standing Order on Personal Devices for purposes of the summary judgment and Daubert motions hearing scheduled for November 20, 2024. Signed by Judge Jennifer L. Hall on 11/19/2024. (ceg) (Entered: 11/19/2024)
11/18/2024
  • Motionby Δ
MOTION for Exemption of Persons from the District Court of Delaware's May 2024 Standing Order on Personal Devices - filed by Amgen Inc.. (Vangellow, Stephanie) (Entered: 11/18/2024)
11/18/2024 NOTICE of Supplemental Authority in Support of Its Memorandum of Law in Opposition to Amgen's Motion for Summary Judgment by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A)(Wilks, David) (Entered: 11/18/2024)
10/16/2024Pro Hac Vice Attorney Betty X. Yang for Amgen Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (cdd) (Entered: 10/16/2024)
10/10/2024Pro Hac Vice Attorney Samuel Liversidge for Amgen Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (scs) (Entered: 10/15/2024)
10/10/2024
  • Motion to Appear Pro Hac Vice
SO ORDERED, re 395 Motion for Pro Hac Vice Appearance of Attorney Samuel Liversidge and Betty X. Yang filed by Amgen Inc. Ordered by Judge Jennifer L. Hall on 10/10/2024. (ceg) (Entered: 10/10/2024)
10/10/2024396Pro Hac Vice Fee - Credit Card Payment received for Samuel Liversidge and Betty X. Yang. ( re 395 MOTION for Pro Hac Vice Appearance of Attorney Samuel Liversidge and Betty X. Yang )( Payment of $ 100, receipt number ADEDC-4520860).(Vangellow, Stephanie) (Entered: 10/10/2024)
10/10/2024
  • Motion to Appear Pro Hac Viceby Δ
MOTION for Pro Hac Vice Appearance of Attorney Samuel Liversidge and Betty X. Yang - filed by Amgen Inc.. (Vangellow, Stephanie) (Entered: 10/10/2024)
9/30/2024REDACTED VERSION of 391 Response to Objections by Amgen Inc.. (Vangellow, Stephanie) (Entered: 09/30/2024)
9/25/2024Remark: D.I. 385 has been unsealed. (lih) (Entered: 09/25/2024)
9/24/2024393
  • Order
ORAL ORDER re 392 Letter: Having reviewed Plaintiff's letter, oral argument will be heard at the November 20, 2024 motion hearing regarding objections to Judge Fallon's Order. Ordered by Judge Jennifer L. Hall on 9/24/2024. (ceg) (Entered: 09/24/2024)
9/24/2024 Letter to The Honorable Jennifer L. Hall from Scott B.Czerwonka regarding Request for Oral Argument - re 387 Objections,. (Czerwonka, Scott) (Entered: 09/24/2024)
9/23/2024
  • Responseby Δ
[SEALED] RESPONSE TO OBJECTIONS by Amgen Inc. re 387 Objections, . (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 09/23/2024)
9/16/2024REDACTED VERSION of 387 Objections, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Certification pursuant to Standing Order for Objections filed under Fed. R. Civ. P. 72, Dated March 7, 2022)(Czerwonka, Scott) (Entered: 09/16/2024)
9/13/2024REDACTED VERSION of 382 Letter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Text of Proposed Order)(Czerwonka, Scott) (Entered: 09/13/2024)
9/13/2024REDACTED VERSION of 383 Letter by Amgen Inc.. (Attachments: # 1 Appendix Declaration, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10)(Vangellow, Stephanie) (Entered: 09/13/2024)
9/9/2024[SEALED] OBJECTIONS by Regeneron Pharmaceuticals, Inc. to 385 Memorandum and Order,, Terminate Hearings, . (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Certification pursuant to Standing Order for Objections filed under Fed. R. Civ. P. 72, Dated March 7, 2022, # 4 Certificate of Service)(Czerwonka, Scott) (Entered: 09/09/2024)
9/3/2024
  • Motion
CORRECTING ENTRY: D.I. 320 -2, 320 -4, 324 , 325 , 326 , 327 -1, 333 -1 have been replaced with corrected under seal versions per the parties' joint request. (ceg) (Entered: 09/03/2024)
8/27/2024SO ORDERED, re 386 STIPULATION TO EXTEND TIME to file REDACTED versions of 382 and 383 to 9/13/2024. Signed by Judge Sherry R. Fallon on 8/27/2024. (Polito, Rebecca) (Entered: 08/27/2024)
8/27/2024 STIPULATION TO EXTEND TIME to file REDACTED versions of 382 and 383 to 9/13/2024 - filed by Amgen Inc.. (Vangellow, Stephanie) (Entered: 08/27/2024)
8/26/2024
  • Order
MEMORANDUM AND ORDER re 355 MOTION for Teleconference to Resolve Privilege Dispute. IT IS FURTHER ORDERED that the discovery dispute teleconference set in this matter for August 28, 2024 at 2:00 PM is CANCELLED. Signed by Judge Sherry R. Fallon on 8/26/2024.This order has been emailed to local counsel. (Polito, Rebecca) (Entered: 08/26/2024)
8/26/2024Pro Hac Vice Attorney Kate Swisher for Amgen Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mws) (Entered: 08/26/2024)
8/21/2024 NOTICE of Defendant's Response to Plaintiff's Notice of Supplemental Authority by Amgen Inc. re 373 Notice (Other), (Sharp, Melanie) (Entered: 08/21/2024)
8/21/2024[SEALED] Letter to Judge Fallon from Melanie K. Sharp regarding privilege dispute. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 08/21/2024)
8/20/2024CORRECTING ENTRY: The proposed order previously filed separately as D.I. 383 has been deleted and attached to D.I. 382 . Counsel is advised that the proposed order should be filed as an attachment and not separately when filing a discovery dispute submission. (lih) (Entered: 08/20/2024)
8/20/2024[SEALED] Letter to the Honorable Sherry R. Fallon from David E. Wilks regarding Privilege Dispute. (Attachments: # 1 Certificate of Service)(Wilks, David) (Additional attachment(s) added on 8/20/2024: # 2 Text of Proposed Order) (lih). (Entered: 08/20/2024)
8/20/2024381
  • Order
ORAL ORDER: At the time the scheduling order was entered, this case was scheduled for trial on November 12, 2024, before Judge Richard G. Andrews. The case was among the hundreds of cases reassigned to me upon my appointment as a district judge. The Court has endeavored to keep as many previously-scheduled trials on the calendar as possible; however, the Court cannot accommodate a 7-day jury trial in November 2024, particularly in view of the 12 pending summary judgment and Daubert motions that need to be decided prior to trial. A hearing on the pending summary judgment and Daubert motions is scheduled for November 20, 2024, at 10:00 AM in Courtroom 6D. The trial and the pretrial conference are CONTINUED to a date TBD. Ordered by Judge Jennifer L. Hall on 8/20/2024. (ceg) (Entered: 08/20/2024)
8/13/2024REDACTED VERSION of 354 Declaration,, by Amgen Inc.. (Vangellow, Stephanie) (Entered: 08/13/2024)
8/13/2024REDACTED VERSION of 353 Reply Brief by Amgen Inc.. (Vangellow, Stephanie) (Entered: 08/13/2024)
8/13/2024REDACTED VERSION of 352 Declaration, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5)(Czerwonka, Scott) (Entered: 08/13/2024)
8/13/2024REDACTED VERSION of 350 Declaration, by Amgen Inc.. (Vangellow, Stephanie) (Entered: 08/13/2024)
8/13/2024REDACTED VERSION of 349 Statement, by Amgen Inc.. (Vangellow, Stephanie) (Entered: 08/13/2024)
8/13/2024REDACTED VERSION of 348 Reply Brief by Amgen Inc.. (Vangellow, Stephanie) (Entered: 08/13/2024)
8/13/2024REDACTED VERSION of 351 Reply Brief, by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 08/13/2024)
8/12/2024 NOTICE of Supplemental Authority in Support of Its Memorandum of Law in Opposition to Amgen's Motion for Summary Judgment by Regeneron Pharmaceuticals, Inc. re 324 Memorandum in Opposition, (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Wilks, David) (Entered: 08/12/2024)
7/30/2024REDACTED VERSION of 333 Declaration,, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1-18, # 2 Exhibit 19 Part I of IV, # 3 Exhibit 19 Part II of IV, # 4 Exhibit 19 Part III of IV, # 5 Exhibit 19 Part IV of IV, # 6 Exhibit 20 - 31, # 7 Exhibit 32 - 36)(Czerwonka, Scott) (Entered: 07/30/2024)
7/30/2024REDACTED VERSION of 332 Answering Brief in Opposition, by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 07/30/2024)
7/30/2024REDACTED VERSION of 328 Declaration, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 43)(Czerwonka, Scott) (Entered: 07/30/2024)
7/30/2024REDACTED VERSION of 327 Declaration,, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1-50, # 2 Exhibit 51-76, # 3 Exhibit 77, # 4 Exhibit 78, # 5 Exhibit 79 Part I of IV, # 6 Exhibit 79 Part II of IV, # 7 Exhibit 79 Part III of IV, # 8 Exhibit 79 Part IV of IV, # 9 Exhibit 80-100, # 10 Exhibit 101-150, # 11 Exhibit 151-202)(Czerwonka, Scott) (Entered: 07/30/2024)
7/30/2024REDACTED VERSION of 326 Statement, by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 07/30/2024)
7/30/2024REDACTED VERSION of 325 Statement, by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 07/30/2024)
7/30/2024REDACTED VERSION of 324 Memorandum in Opposition, by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 07/30/2024)
7/30/2024REDACTED VERSION of 331 Declaration,, by Amgen Inc.. (Attachments: # 1 Part 2 of 2)(Vangellow, Stephanie) (Entered: 07/30/2024)
7/30/2024REDACTED VERSION of 330 Answering Brief in Opposition, by Amgen Inc.. (Vangellow, Stephanie) (Entered: 07/30/2024)
7/23/2024
  • Motion to Extend Time to File Brief
SO ORDERED, re 362 Stipulation and Order to Extend Time to File Redacted Versions. The parties' answering briefs (D.I. 324, D.I. 325, D.I. 326, D.I. 327, D.I. 328, D.I. 330, 331, D.I. 332, D.I. 333) is extended to and including July 30, 2024. The parties' reply briefs (D.I. 348, D.I. 349, D.I. 350, D.I. 351, D.I. 352, D.I. 353, D.I. 354) is extended to and including August 13, 2024. Signed by Judge Jennifer L. Hall on 7/23/2024. (ceg) (Entered: 07/23/2024)
7/22/2024
  • Motion to Extend Time to File Briefby Δ
STIPULATION TO EXTEND TIME to File Redacted Versions of the Parties' Answering Briefs and Reply Briefs to the dates set forth in the Stipulation - filed by Amgen Inc.. (Vangellow, Stephanie) (Entered: 07/22/2024)
7/18/2024 Letter to Honorable Jennifer L. Hall from Scott B. Czerwonka regarding Request for Oral Argument - re 330 Answering Brief in Opposition, 351 Reply Brief, 352 Declaration, 319 MEMORANDUM in Support, 331 Declaration,, 318 MOTION to Exclude Testimony of Dr. Eric M. Gaier; Dr. Lauren J. Stiroh and Ms. Deborah Gan , 320 Declaration,. (Czerwonka, Scott) (Entered: 07/18/2024)
7/18/2024 Letter to the Honorable Jennifer L. Hall from Melanie K. Sharp regarding Request for Oral Argument - re 315 MOTION [Amgen Inc.'s Motion to Exclude Expert Testimony Proffered by Regeneron] , 307 MOTION for Summary Judgment [Amgen Inc.'s Motions for Summary Judgment]. (Sharp, Melanie) (Entered: 07/18/2024)
7/18/2024359
  • Order
SO ORDERED- re 355 MOTION for Teleconference to Resolve Privilege Dispute. A Discovery Dispute Motion Hearing is set for 8/28/2024 at 02:00 PM before Judge Sherry R. Fallon. Plaintiff's opening submission, limited to no more than four pages, is due by no later than 11:00 AM on 8/20/2024. The defendant's responsive submission, limited to no more than four pages, is due by no later than 11:00 AM on 8/21/2024. IT IS FURTHER ORDERED that the clawed-back documents that are subject of the dispute shall be provided to the court for in camera review on the date the moving submission is due. In preparation for this teleconference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Order regarding discovery matters available at www.ded.uscourts.gov/judge/magistrate-judge-sherry-r-fallon. The plaintiff should obtain court reporting services for the conference, with the cost to be shared equally between both sides. No later than 8/27/2024 at 11:00 a.m., the parties shall send a joint email to Rebecca_Polito@ded.uscourts.gov containing (i) the name of the court reporter; (ii) the name of the court reporting agency; and (iii) confirmation that the court reporter has been provided with the court's AT&T dial-in information. The Court may choose to resolve the disputes prior to the telephone conference and will, in that event, cancel the conference. Set Deadlines: (Moving Submission due by no later than 11:00 A.M. on 8/20/2024, Responsive submission due by no later than 11:00 A.M. on 8/21/2024). Signed by Judge Sherry R. Fallon on 7/18/2024. (lih) (Entered: 07/18/2024)
7/18/2024358
  • Order
ORAL ORDER REFERRING MOTION: IT IS HEREBY ORDERED that the Motion for Teleconference to Resolve Privilege Dispute (D.I. 355 ) is now REFERRED to Magistrate Judge Sherry R. Fallon. Ordered by Judge Jennifer L. Hall on 7/18/2024. (ceg) (Entered: 07/18/2024)
7/16/2024SO ORDERED, re 356 Stipulation and Order to Extend Time to File Redacted Versions of D.I. 348-354 to July 30, 2024. Signed by Judge Jennifer L. Hall on 7/16/2024. (ceg) (Entered: 07/16/2024)
7/16/2024 STIPULATION TO EXTEND TIME to File Redacted Versions to July 30, 2024 - filed by Amgen Inc.. (Vangellow, Stephanie) (Entered: 07/16/2024)
7/15/2024
  • Motionby Π
MOTION for Teleconference to Resolve Privilege Dispute - filed by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 07/15/2024)
7/15/2024[SEALED] DECLARATION re 353 Reply Brief [Declaration of Eric J. Stock in Support of Amgen Inc.'s Reply in Support of its Motion to Exclude Certain Expert Testimony Proffered by Regeneron] by Amgen Inc.. (Attachments: # 1 Exhibit 35, # 2 Exhibit 36, # 3 Exhibit 37, # 4 Exhibit 38, # 5 Exhibit 39, # 6 Exhibit 40, # 7 Exhibit 41, # 8 Exhibit 42, # 9 Exhibit 43, # 10 Exhibit 44, # 11 Exhibit 45, # 12 Exhibit 46, # 13 Certificate of Service)(Sharp, Melanie) (Entered: 07/15/2024)
7/15/2024
  • Motion to Exclude Testimonyby Δ
[SEALED] REPLY BRIEF re 315 MOTION [Amgen Inc.'s Motion to Exclude Expert Testimony Proffered by Regeneron] filed by Amgen Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 07/15/2024)
7/15/2024[SEALED] DECLARATION re 351 Reply Brief, Declaration of Eric S. Hochstadt in support of Regeneron Pharmaceuticals, Inc.'s Reply in support of its Motion to Exclude Expert Testimony Proffered by Amgen by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Certificate of Service)(Czerwonka, Scott) (Entered: 07/15/2024)
7/15/2024
  • Motion to Exclude Testimonyby Π
[SEALED] REPLY BRIEF re 318 MOTION to Exclude Testimony of Dr. Eric M. Gaier; Dr. Lauren J. Stiroh and Ms. Deborah Gan filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) (Entered: 07/15/2024)
7/12/2024[SEALED] DECLARATION re 348 Reply Brief [Declaration of Ashley Johnson in Support of Amgen Inc.'s Reply Brief in Support of its Motions for Summary Judgment] by Amgen Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Certificate of Service)(Sharp, Melanie) (Entered: 07/12/2024)
7/12/2024[SEALED] STATEMENT re 325 Statement, [Amgen Inc.'s Response to Regeneron Pharmaceuticals, Inc.'s Concise Statement of Facts in Response to Amgen's Motions for Summary Judgment] by Amgen Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 07/12/2024)
7/12/2024
  • Motion for Summary Judgmentby Δ
[SEALED] REPLY BRIEF re 307 MOTION for Summary Judgment [Amgen Inc.'s Motions for Summary Judgment] filed by Amgen Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 07/12/2024)
7/3/2024REDACTED VERSION of 317 Declaration,,, of Eric J. Stock in Support of Amgen Inc.'s Motion to Exclude Expert Testimony Proffered by Regeneron by Amgen Inc.. (Sharp, Melanie) (Entered: 07/03/2024)
7/3/2024REDACTED VERSION of 316 Opening Brief in Support, of 315 MOTION by Amgen Inc.. (Sharp, Melanie) (Entered: 07/03/2024)
7/3/2024REDACTED VERSION of 311 Exhibit to a Document, Declaration of Ashley Johnson - VOLUME 2 by Amgen Inc. (Attachments: # 1 Part 2)(Sharp, Melanie) Modified on 7/3/2024 (ceg). (Entered: 07/03/2024)
7/3/2024REDACTED VERSION of 310 Declaration of Ashley Johnson - VOLUME 1, by Amgen Inc. (Attachments: # 1 Part 2)(Sharp, Melanie) Modified on 7/3/2024 (ceg). (Entered: 07/03/2024)
7/3/2024REDACTED VERSION of 309 Opening Brief in Support, 307 MOTION for Summary Judgment by Amgen Inc.. (Sharp, Melanie) (Entered: 07/03/2024)
7/3/2024REDACTED VERSION of 308 Statement, Amgen Inc.'s Motions for Summary Judgment] [Amgen Inc.'s Concise Statements of Facts in Support of Its Motions for Summary Judgment by Amgen Inc.. (Sharp, Melanie) (Entered: 07/03/2024)
7/3/2024REDACTED VERSION of 320 Declaration, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-F, # 2 Exhibit G-K, # 3 Exhibit L-P, # 4 Exhibit Q-U)(Czerwonka, Scott) (Entered: 07/03/2024)
7/3/2024REDACTED VERSION of 319 MEMORANDUM in Support, by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 07/03/2024)
7/2/2024339
  • OrderDenied
ORAL ORDER: The Motion for a Status Conference (D.I. 338 ) is DENIED. The Court will determine the amount of trial days at the pretrial conference. Ordered by Judge Jennifer L. Hall on 7/2/2024. (ceg) (Entered: 07/02/2024)
6/28/2024
  • Motionby Π
MOTION for Status Conference - filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Rule 7.1.1 Statement)(Czerwonka, Scott) (Entered: 06/28/2024)
6/28/2024CORRECTING ENTRY: The docket text for D.I. 337 has been modified to reflect the proper Stipulation and Order. (ceg) (Entered: 06/28/2024)
6/28/2024SO ORDERED, re 336 Amended Stipulation and Order to Extend Time to file Redacted Versions of of Amgen's Motion for Summary Judgment (D.I. 308, 309, 310, 311) and the parties' Motions to Exclude Expert Testimony (D.I. 316, 317, 319, 320) to July 3, 2024. Signed by Judge Jennifer L. Hall on 6/28/2024. (ceg) Modified on 6/28/2024 (ceg). (Entered: 06/28/2024)
6/28/2024Amended STIPULATION TO EXTEND TIME to file Redacted Versions of Amgen's Motion for Summary Judgment (D.I. 308, 309, 310, 311) and the parties' Motions to Exclude Expert Testimony (D.I. 316, 317, 319, 320) to July 3, 2024 - filed by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 06/28/2024)
6/28/2024SO ORDERED, re 334 Stipulation and Order to Extend Time to file Redacted Versions of Regeneron Pharmaceuticals, Inc. Memorandum of Law in Opposition to Amgen Inc. Motion for Summary Judgement (D.I. 324, D.I. 325, D.I. 326, D.I. 327, D.I. 328), and the parties Answering Briefs and supporting Declarations in Opposition to the Motions to Exclude Expert Testimony (D.I. 330, D.I. 331, D.I. 332, D.I. 333) to July 23, 2024. Signed by Judge Jennifer L. Hall on 6/28/2024. (ceg) (Entered: 06/28/2024)
6/27/2024 STIPULATION TO EXTEND TIME to file Redacted Versions of Regeneron Pharmaceuticals, Inc. Memorandum of Law in Opposition to Amgen Inc. Motion for Summary Judgement (D.I. 324, D.I. 325, D.I. 326, D.I. 327, D.I. 328), and the parties Answering Briefs and supporting Declarations in Opposition to the Motions to Exclude Expert Testimony (D.I. 330, D.I. 331, D.I. 332, D.I. 333) to July 23, 2024 - filed by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 06/27/2024)
6/25/2024[SEALED] DECLARATION re 332 Answering Brief in Opposition, Declaration of Eric S. Hochstadt in Support of Regeneron Pharmaceuticals, Inc.'s Opposition to Amgen Inc.'s Motion to Exclude Expert Testimony Proffered by Regeneron by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1 - 18, # 2 Exhibit 19 Part I of IV, # 3 Exhibit 19 Part II of IV, # 4 Exhibit 19 Part III of IV, # 5 Exhibit 19 Part IV of IV, # 6 Exhibit 20 - 31, # 7 Exhibit 32 - 36, # 8 Certificate of Service)(Czerwonka, Scott) (Attachment 1 replaced on 9/3/2024) (ceg). (Entered: 06/25/2024)
6/25/2024
  • Motion to Exclude Testimony
[SEALED] ANSWERING BRIEF in Opposition re 315 MOTION [Amgen Inc.'s Motion to Exclude Expert Testimony Proffered by Regeneron] filed by Regeneron Pharmaceuticals, Inc. Reply Brief due date per 2052 Stipulation is 7/15/2024. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 6/26/2024 (ceg). (Entered: 06/25/2024)
6/25/2024[SEALED] DECLARATION re 330 Answering Brief in Opposition, [Declaration of Eric J. Stock in Support of Amgen Inc.'s Answering Brief in Opposition to Regeneron's Motion to Exclude Testimony of Dr. Eric M. Gaier; Dr. Lauren J. Stiroh; and Ms. Deborah Gan] by Amgen Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Certificate of Service)(Sharp, Melanie) (Entered: 06/25/2024)
6/25/2024
  • Motion to Exclude Testimony
[SEALED] ANSWERING BRIEF in Opposition re 318 MOTION to Exclude Testimony of Dr. Eric M. Gaier; Dr. Lauren J. Stiroh and Ms. Deborah Gan filed by Amgen Inc. Reply Brief due date per 205 Stipulation is 7/15/2024. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 6/26/2024 (ceg). (Entered: 06/25/2024)
6/24/2024CORRECTING ENTRY: The "Motions No Longer Referred" remark has been removed. Filed in error. (ceg) (Entered: 06/24/2024)
6/21/2024 EXHIBIT re 328 Declaration, Certificate of Service to Declaration Richard O'Neal in Support of Regeneron Pharmaceuticals, Inc.'s Memorandum of Law in Opposition to Amgen Inc.'s Motion for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 06/21/2024)
6/21/2024[SEALED] DECLARATION re 324 Memorandum in Opposition, Declaration of Richard O'Neal in Support of Regeneron Pharmaceuticals, Inc.'s Memorandum in Opposition to Amgen Inc.'s Motion for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 43)(Czerwonka, Scott) (Entered: 06/21/2024)
6/21/2024[SEALED] DECLARATION re 324 Memorandum in Opposition, of Eric S. Hochstadt in Support of Regeneron Pharmaceuticals, Inc.'s Memorandum in Law in Opposition of Amgen Inc.'s Motion for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1 - 50, # 2 Exhibit 51 - 76, # 3 Exhibit 77, # 4 Exhibit 78, # 5 Exhibit 79 Part I of IV, # 6 Exhibit 79 Part II of IV, # 7 Exhibit 79 Part III of IV, # 8 Exhibit 79 Part IV of IV, # 9 Exhibit 80 - 100, # 10 Exhibit 101 - 150, # 11 Exhibit 151 - 202, # 12 Certificate of Service)(Czerwonka, Scott) (Attachment 1 replaced on 9/3/2024) (ceg). (Entered: 06/21/2024)
6/21/2024[SEALED] STATEMENT re 308 Statement, Regeneron Pharmaceuticals, Inc.'s Response to Amgen Inc.'s Concise Statement of Facts in Support of Its Motion for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) (Main Document 326 replaced on 9/3/2024) (ceg). (Entered: 06/21/2024)
6/21/2024[SEALED] STATEMENT re 308 Statement, 324 Memorandum in Opposition, Regeneron Pharmaceuticals, Inc.'s Concise Statement of Facts in Response to Amgen Inc.'s Motion for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) (Main Document 325 replaced on 9/3/2024) (ceg). (Entered: 06/21/2024)
6/21/2024
  • Motion for Summary Judgment
[SEALED] MEMORANDUM in Opposition re 307 MOTION for Summary Judgment [Amgen Inc.'s Motions for Summary Judgment] filed by Regeneron Pharmaceuticals, Inc. Reply Brief due date per 205 Stipulation is 7/12/2024. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 6/24/2024 (ceg). (Main Document 324 replaced on 9/3/2024) (ceg). (Entered: 06/21/2024)
6/13/2024
  • Order
SO ORDERED, re 323 Stipulation and Order to Extend Deadline to file Redacted Versions of Amgen's Motion for Summary Judgment (D.I. 308 , 309 , 310 , 311 ) and the parties' Motions to Exclude Expert Testimony (D.I. 316 , 317 , 319 , 320 ) to June 28, 2024. Ordered by Judge Jennifer L. Hall on 6/13/2024. (ceg) (Entered: 06/13/2024)
6/13/2024
  • Motion
STIPULATION to Extend Deadline to file Redacted Versions of Amgen's Motion for Summary Judgment (D.I. 308, 309, 310, 311) and the parties' Motions to Exclude Expert Testimony (D.I. 316, 317, 319, 320) to June 28, 2024, by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) Modified on 6/13/2024 (ceg). (Entered: 06/13/2024)
5/31/2024SO ORDERED, re 322 Stipulation and Order to Extend Time to file Redacted Versions of the parties' Motions to Exclude Expert Testimony (D.I. 316 , 317 , 319 , 320 ) to June 14, 2024. Ordered by Judge Jennifer L. Hall on 5/31/2024. (ceg) (Entered: 05/31/2024)
5/31/2024 STIPULATION TO EXTEND TIME to file Redacted Versions of the Parties' Motions to Exclude Expert Testimony to June 14, 2024 - filed by Amgen Inc.. (Vangellow, Stephanie) (Entered: 05/31/2024)
5/29/2024CORRECTING ENTRY: The pdf for the Certificate of Service found at D.I. 321 has been replaced with a corrected version to include a case caption. (ceg) (Entered: 05/29/2024)
5/29/2024CERTIFICATE OF SERVICE of (1) Declaration of David E. Wilks in Support of Plaintiff Regeneron Pharmaceuticals, Incs Motion to Exclude Testimony of Dr. Eric M. Gaier; Dr. Lauren J. Stiroh; and Ms. Deborah Gan and (2) Plaintiff Regeneron Pharmaceuticals, Incs Memorandum in Support of its Motion to Exclude Testimony of Dr. Eric M. Gaier; Dr. Lauren J. Stiroh; and Ms. Deborah Gan by Regeneron Pharmaceuticals, Inc. re 319 MEMORANDUM in Support, 320 Declaration, (Wilks, David) Modified on 5/29/2024 (ceg). (Main Document 321 replaced on 5/29/2024) (ceg). (Entered: 05/29/2024)
5/29/2024DEFICIENCY NOTICE by the Court issued to Plaintiff re 319 Memorandum in Support, 320 Declaration. These filings do not comply with Local Rule 5.2(b)(1). Plaintiff is directed to supplement the docket accordingly with a certificate of service. (ceg) (Entered: 05/29/2024)
5/29/2024Reset Briefing Schedule re 315 MOTION to Exclude Expert Testimony Proffered by Regeneron, 318 MOTION to Exclude Testimony of Dr. Eric M. Gaier; Dr. Lauren J. Stiroh and Ms. Deborah Gan: Answering Brief due 6/25/2024; Reply Brief due 7/15/2024 per D.I. 205 . (ceg) (Entered: 05/29/2024)
5/28/2024[SEALED] DECLARATION re 319 MEMORANDUM in Support, 318 MOTION to Exclude Testimony of Dr. Eric M. Gaier; Dr. Lauren J. Stiroh and Ms. Deborah Gan by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-F, # 2 Exhibit G-K, # 3 Exhibit L-P, # 4 Exhibit Q-U)(Wilks, David) (Attachment 2 replaced on 9/3/2024) (ceg). (Attachment 4 replaced on 9/3/2024) (ceg). (Entered: 05/28/2024)
5/28/2024
  • Motion to Exclude Testimony
[SEALED] MEMORANDUM in Support re 318 MOTION to Exclude Testimony of Dr. Eric M. Gaier; Dr. Lauren J. Stiroh and Ms. Deborah Gan, filed by Regeneron Pharmaceuticals, Inc. Answering Brief/Response due date per 205 Stipulation is 6/25/2024. (Wilks, David) Modified on 5/29/2024 (ceg). (Entered: 05/28/2024)
5/28/2024
  • Motion to Exclude Testimonyby Π
MOTION to Exclude Testimony of Dr. Eric M. Gaier; Dr. Lauren J. Stiroh and Ms. Deborah Gan - filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Text of Proposed Order)(Wilks, David) (Entered: 05/28/2024)
5/28/2024[SEALED] DECLARATION re 316 Opening Brief in Support, [Declaration of Eric J. Stock in Support of Amgen Inc.'s Motion to Exclude Expert Testimony Proffered by Regeneron] by Amgen Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Certificate of Service)(Sharp, Melanie) (Entered: 05/28/2024)
5/28/2024[SEALED] OPENING BRIEF in Support re 315 MOTION to Exclude Expert Testimony Proffered by Regeneron, filed by Amgen Inc. Answering Brief/Response due date per 205 Stipulation is 6/25/2024. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 5/29/2024 (ceg). (Entered: 05/28/2024)
5/28/2024
  • Motion to Exclude Testimony
MOTION to Exclude Expert Testimony Proffered by Regeneron - filed by Amgen Inc. (Sharp, Melanie) Modified on 5/29/2024 (ceg). (Entered: 05/28/2024)
5/28/2024SO ORDERED, re 313 Stipulation and Order to Extend Time to File Redacted Versions of D.I. 308, D.I. 309, D.I. 310 and D.I. 311 to June 14, 2024. Signed by Judge Jennifer L. Hall on 5/28/2024. (ceg) (Entered: 05/28/2024)
5/24/2024 STIPULATION TO EXTEND TIME to File Redactions of D.I. 308, D.I. 309, D.I. 310 and D.I. 311 to June 14, 2024 - filed by Amgen Inc.. (Vangellow, Stephanie) (Entered: 05/24/2024)
5/22/2024NOTICE of filing the following Non-Paper material(s) in multi media format: Exhibits 31, 51, and 60, to Defendant Amgen Inc.'s Opening Brief in Support of its Motion for Summary Judgment. Original Non-paper material(s) to be filed with the Clerk's Office. Notice filed by Stephanie Vangellow on behalf of Amgen Inc. (Vangellow, Stephanie) (Entered: 05/22/2024)
5/22/2024[SEALED] EXHIBIT re 310 Declaration of Ashley Johnson in Support of Amgen Inc.'s Opening Brief in Support of its Motions for Summary Judgment (Volume 2 of 2: Exhibits 66 - 164), by Amgen Inc. (Attachments: # 1 Exhibit 66, # 2 Exhibit 67, # 3 Exhibit 68, # 4 Exhibit 69, # 5 Exhibit 70, # 6 Exhibit 71, # 7 Exhibit 72, # 8 Exhibit 73, # 9 Exhibit 74, # 10 Exhibit 75, # 11 Exhibit 76, # 12 Exhibit 77, # 13 Exhibit 78, # 14 Exhibit 79, # 15 Exhibit 80, # 16 Exhibit 81, # 17 Exhibit 82, # 18 Exhibit 83, # 19 Exhibit 84, # 20 Exhibit 85, # 21 Exhibit 86, # 22 Exhibit 87, # 23 Exhibit 88, # 24 Exhibit 89, # 25 Exhibit 90, # 26 Exhibit 91, # 27 Exhibit 92, # 28 Exhibit 93, # 29 Exhibit 94, # 30 Exhibit 95, # 31 Exhibit 96, # 32 Exhibit 97, # 33 Exhibit 98, # 34 Exhibit 99, # 35 Exhibit 100, # 36 Exhibit 101, # 37 Exhibit 102, # 38 Exhibit 103, # 39 Exhibit 104, # 40 Exhibit 105, # 41 Exhibit 106, # 42 Exhibit 107, # 43 Exhibit 108, # 44 Exhibit 109, # 45 Exhibit 110, # 46 Exhibit 111, # 47 Exhibit 112, # 48 Exhibit 113, # 49 Exhibit 114, # 50 Exhibit 115, # 51 Exhibit 116, # 52 Exhibit 117, # 53 Exhibit 118, # 54 Exhibit 119, # 55 Exhibit 120, # 56 Exhibit 121, # 57 Exhibit 122, # 58 Exhibit 123, # 59 Exhibit 124, # 60 Exhibit 125, # 61 Exhibit 126, # 62 Exhibit 127, # 63 Exhibit 128, # 64 Exhibit 129, # 65 Exhibit 130, # 66 Exhibit 131, # 67 Exhibit 132, # 68 Exhibit 133, # 69 Exhibit 134, # 70 Exhibit 135, # 71 Exhibit 136, # 72 Exhibit 137, # 73 Exhibit 138, # 74 Exhibit 139, # 75 Exhibit 140, # 76 Exhibit 141, # 77 Exhibit 142, # 78 Exhibit 143, # 79 Exhibit 144, # 80 Exhibit 145, # 81 Exhibit 146, # 82 Exhibit 147, # 83 Exhibit 148, # 84 Exhibit 149, # 85 Exhibit 150, # 86 Exhibit 151, # 87 Exhibit 152, # 88 Exhibit 153, # 89 Exhibit 154, # 90 Exhibit 155, # 91 Exhibit 156, # 92 Exhibit 157, # 93 Exhibit 158, # 94 Exhibit 159, # 95 Exhibit 160, # 96 Exhibit 161, # 97 Exhibit 162, # 98 Exhibit 163, # 99 Exhibit 164, # 100 Certificate of Service)(Sharp, Melanie) Modified on 5/22/2024 (ceg). (Entered: 05/22/2024)
5/22/2024[SEALED] DECLARATION re 309 Opening Brief in Support [Declaration of Ashley Johnson in Support of Amgen Inc.'s Opening Brief in Support of its Motions for Summary Judgment Volume 1 of 2: Exhibits 1 - 65] by Amgen Inc.. (Attachments: # 1 Cover Page Volume 1 of 2, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18, # 20 Exhibit 19, # 21 Exhibit 20, # 22 Exhibit 21, # 23 Exhibit 22, # 24 Exhibit 23, # 25 Exhibit 24, # 26 Exhibit 25, # 27 Exhibit 26, # 28 Exhibit 27, # 29 Exhibit 28, # 30 Exhibit 29, # 31 Exhibit 30, # 32 Exhibit 31, # 33 Exhibit 32, # 34 Exhibit 33, # 35 Exhibit 34, # 36 Exhibit 35, # 37 Exhibit 36, # 38 Exhibit 37, # 39 Exhibit 38, # 40 Exhibit 39, # 41 Exhibit 40, # 42 Exhibit 41, # 43 Exhibit 42, # 44 Exhibit 43, # 45 Exhibit 44, # 46 Exhibit 45, # 47 Exhibit 46, # 48 Exhibit 47, # 49 Exhibit 48, # 50 Exhibit 49, # 51 Exhibit 50, # 52 Exhibit 52, # 53 Exhibit 53, # 54 Exhibit 54, # 55 Exhibit 55, # 56 Exhibit 56, # 57 Exhibit 57, # 58 Exhibit 58, # 59 Exhibit 59, # 60 Exhibit 60, # 61 Exhibit 61, # 62 Exhibit 62, # 63 Exhibit 63, # 64 Exhibit 64, # 65 Exhibit 65, # 66 Certificate of Service)(Sharp, Melanie) (Entered: 05/22/2024)
5/22/2024[SEALED] OPENING BRIEF in Support re 307 MOTION for Summary Judgment [Amgen Inc.'s Motions for Summary Judgment] filed by Amgen Inc. Answering Brief/Response due date per 205 Stipulation is 6/21/2024. (Sharp, Melanie) Modified on 5/22/2024 (ceg). (Entered: 05/22/2024)
5/22/2024[SEALED] STATEMENT re 307 MOTION for Summary Judgment [Amgen Inc.'s Motions for Summary Judgment] [Amgen Inc.'s Concise Statements of Facts in Support of Its Motions for Summary Judgment] by Amgen Inc.. (Attachments: # 1 Exhibit 1 - SUF No. 1, # 2 Exhibit 2 - SUF No. 2, # 3 Exhibit 3 - SUF No. 3, # 4 Certificate of Service)(Sharp, Melanie) (Entered: 05/22/2024)
5/22/2024
  • Motion for Summary Judgmentby Δ
MOTION for Summary Judgment [Amgen Inc.'s Motions for Summary Judgment] - filed by Amgen Inc.. (Sharp, Melanie) (Entered: 05/22/2024)
5/20/2024
  • OrderGranted
SO ORDERED, granting 302 Amgen Inc's Unopposed Application for Entry of Order regarding Format and Length of Summary Judgment and Daubert Briefing. (*See Order for details). Signed by Judge Jennifer L. Hall on 5/20/2024. (ceg) (Entered: 05/20/2024)
5/16/2024
  • Motion to Appear Pro Hac Vice
SO ORDERED, re 304 Motion for Pro Hac Vice Appearance of Attorney Kate Swisher filed by Amgen Inc. Ordered by Judge Jennifer L. Hall on 5/16/2024. (ceg) (Entered: 05/16/2024)
5/16/2024305Pro Hac Vice Fee - Credit Card Payment received for Kate Swisher. ( re 304 MOTION for Pro Hac Vice Appearance of Attorney Kate Swisher )( Payment of $ 50, receipt number ADEDC-4409092).(Vangellow, Stephanie) (Entered: 05/16/2024)
5/16/2024
  • Motion to Appear Pro Hac Viceby Δ
MOTION for Pro Hac Vice Appearance of Attorney Kate Swisher - filed by Amgen Inc.. (Vangellow, Stephanie) (Entered: 05/16/2024)
5/16/2024Official Transcript of Discovery Dispute Teleconference held on 03-19-2024 before Judge Hall. Court Reporter Stacy Ingram,Email: stacy_ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 6/6/2024. Redacted Transcript Deadline set for 6/17/2024. Release of Transcript Restriction set for 8/14/2024. (Ingram, Stacy) (Entered: 05/16/2024)
5/14/2024
  • Motion
Unopposed MOTION for Entry of Order regarding Format and Length of Summary Judgment and Daubert Briefing - filed by Amgen Inc. (Sharp, Melanie) Modified on 5/14/2024 (ceg). (Entered: 05/14/2024)
5/14/2024Official Transcript of Hearing held on 01-04-2024 before Judge Hall. Court Reporter/Transcriber Stacy Ingram,Email: stacy_ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 6/4/2024. Redacted Transcript Deadline set for 6/14/2024. Release of Transcript Restriction set for 8/12/2024. (Ingram, Stacy) (Entered: 05/14/2024)
5/3/2024 NOTICE of Withdrawal of Pro Hac Vice Counsel, William Cooke by Regeneron Pharmaceuticals, Inc. (Wilks, David) (Entered: 05/03/2024)
4/30/2024 NOTICE of Withdrawal of Counsel, Taylor E. Hallowell by Amgen Inc. (Higgins, James) (Entered: 04/30/2024)
4/26/2024NOTICE OF SERVICE of Defendant's Supplemental Responses and Objections to Plaintiff's Interrogatory No. 2 filed by Amgen Inc..(Hallowell, Taylor) (Entered: 04/26/2024)
4/26/2024NOTICE OF SERVICE of Plaintiff Regeneron Pharmaceuticals, Inc.s First Supplemental Objections and Responses to Defendant Amgen Inc.s Second and Third Set of Interrogatories (Nos. 8,17,19) and Plaintiff Regeneron Pharmaceuticals, Inc.s Designated 30(b)(6) Testimony in Response to Defendant Amgen Inc.s Rule 30(b)(6) Deposition Topics 18-19 filed by Regeneron Pharmaceuticals, Inc..(Wilks, David) (Entered: 04/26/2024)
3/27/2024REDACTED VERSION of 291 Letter, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-H)(Wilks, David) (Entered: 03/27/2024)
3/27/2024REDACTED VERSION of 290 Letter, by Amgen Inc.. (Vangellow, Stephanie) (Entered: 03/27/2024)
3/21/2024SO ORDERED, re 293 Stipulation and Order to Extend Time to File Public Redacted Versions of D.I. 290 and D.I. 291 to March 27, 2024. Signed by Judge Jennifer L. Hall on 3/21/2024. (ceg) (Entered: 03/21/2024)
3/20/2024 STIPULATION and [Proposed] Order to Extend Time to File Public Redacted Versions of D.I. 290 and D.I. 291 to March 27, 2024 by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 03/20/2024)
3/19/2024292
  • OrderDenied
ORAL ORDER: For the reasons stated at today's teleconference, Amgen's discovery motion (D.I. 288 ) is DENIED. Ordered by Judge Jennifer L. Hall on 3/19/2024. (ceg) (Entered: 03/19/2024)
3/19/2024Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute Teleconference held on 3/19/2024. (Court Reporter: Stacy Ingram.) (twk) (Entered: 03/19/2024)
3/15/2024[SEALED] Letter to The Honorable Jennifer L. Hall from David E. Wilks regarding Discovery Dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Certificate of Service)(Wilks, David) (Entered: 03/15/2024)
3/13/2024[SEALED] Letter to the Honorable Jennifer L. Hall from Melanie K. Sharp regarding Discovery Dispute. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Certificate of Service)(Sharp, Melanie) (Entered: 03/13/2024)
3/11/2024289
  • Order
ORAL ORDER Setting Teleconference: The Court has reviewed the Motion for Teleconference to Resolve Discovery Dispute (D.I. 288 ). A discovery dispute teleconference is scheduled for March 19, 2024 at 4:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than March 13, 2024, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than March 15, 2024, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Ordered by Judge Jennifer L. Hall on 3/11/2024. (ceg) (Entered: 03/11/2024)
3/8/2024
  • Motionby Δ
MOTION for Teleconference to Resolve Discovery Dispute - filed by Amgen Inc.. (Sharp, Melanie) (Entered: 03/08/2024)
3/8/2024
  • Motion to Appear Pro Hac Vice
SO ORDERED, re 286 Motion for Pro Hac Vice Appearance of Attorney John Adams filed by Amgen Inc. Ordered by Judge Jennifer L. Hall on 3/8/2024. (ceg) (Entered: 03/08/2024)
3/8/2024287Pro Hac Vice Fee - Credit Card Payment received for John Adams. ( re 286 MOTION for Pro Hac Vice Appearance of Attorney John Adams )( Payment of $ 50, receipt number ADEDC-4356859).(Vangellow, Stephanie) (Entered: 03/08/2024)
3/8/2024
  • Motion to Appear Pro Hac Viceby Δ
MOTION for Pro Hac Vice Appearance of Attorney John Adams - filed by Amgen Inc.. (Vangellow, Stephanie) (Entered: 03/08/2024)
3/7/2024 NOTICE of Subpoena Ad Testificandum to Alina Shipman by Amgen Inc. (Attachments: # 1 Exhibit 1)(Vangellow, Stephanie) (Entered: 03/07/2024)
3/5/2024NOTICE to Take Deposition of CaremarkPCS Health LLC on March 18, 2024 filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Certificate of Service)(Wilks, David) (Entered: 03/05/2024)
3/4/2024 NOTICE of Plaintiff's Cross-Notice of Subpoena Ad Testificandum to Michelle Carnahan by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Exhibit 1)(Czerwonka, Scott) (Entered: 03/04/2024)
2/29/2024NOTICE of Appearance by Stephanie Vangellow on behalf of Amgen Inc. (Vangellow, Stephanie) (Entered: 02/29/2024)
2/29/2024 NOTICE of Subpoena Ad Testificandum to Alina Shipman by Amgen Inc. (Attachments: # 1 Exhibit 1)(Sharp, Melanie) (Entered: 02/29/2024)
2/23/2024 NOTICE of Subpoena Ad Testificandum directed to Suzanne Shugg by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Exhibit 1)(Czerwonka, Scott) (Entered: 02/23/2024)
2/23/2024 NOTICE of Subpoena Ad Testificandum to Michelle Carnahan by Amgen Inc. (Attachments: # 1 Exhibit 1)(Sharp, Melanie) (Entered: 02/23/2024)
2/22/2024
  • Motion to Appear Pro Hac Vice
SO ORDERED, re 277 Motion for Pro Hac Vice Appearance of Attorney Richard J. Doren filed by Amgen Inc. Ordered by Judge Jennifer L. Hall on 2/22/2024. (ceg) (Entered: 02/22/2024)
2/21/2024278Pro Hac Vice Fee - Credit Card Payment received for Richard J. Doren. ( re 277 MOTION for Pro Hac Vice Appearance of Attorney Richard J. Doren )( Payment of $ 50, receipt number ADEDC-4344081).(Hallowell, Taylor) (Entered: 02/21/2024)
2/21/2024
  • Motion to Appear Pro Hac Viceby Δ
MOTION for Pro Hac Vice Appearance of Attorney Richard J. Doren - filed by Amgen Inc.. (Hallowell, Taylor) (Entered: 02/21/2024)
2/21/2024NOTICE to Take Deposition of Leonard Schleifer on February 22, 2024 filed by Amgen Inc..(Hallowell, Taylor) (Entered: 02/21/2024)
2/21/2024
  • Order
SO ORDERED, re 270 Stipulated Order Governing the Disclosure and Non-Disclosure of Certain Information Regarding Experts and Consultants. Signed by Judge Jennifer L. Hall on 2/21/2024. (ceg) (Entered: 02/21/2024)
2/20/2024 NOTICE of Subpoena Ad Testificandum to CaremarkPCS Health, LLC by Amgen Inc. (Attachments: # 1 Exhibit 1)(Hallowell, Taylor) (Entered: 02/20/2024)
2/20/2024 NOTICE of Subpoena Ad Testificandum to CVS Caremark Part D Services, LLC by Amgen Inc. (Attachments: # 1 Exhibit 1)(Hallowell, Taylor) (Entered: 02/20/2024)
2/20/2024 NOTICE of Subpoena Ad Testificandum to CVS Health Corporation by Amgen Inc. (Attachments: # 1 Exhibit 1)(Hallowell, Taylor) (Entered: 02/20/2024)
2/16/2024NOTICE OF SERVICE of (1) Expert Report of Divya Mathur, Ph.D.; (2) Opening Expert Report of Robert H. Eckel, M.D.; (3) Expert Report of Fiona Scott Morton, and (4) Expert Report of Heather Bates, and (5) Amended Expert Report of Fiona Scott Morton filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 02/16/2024)
2/14/2024 PROPOSED Stipulated Order Governing the Disclosure and Non-Disclosure of Certain Information Regarding Experts and Consultants by Regeneron Pharmaceuticals, Inc. (Czerwonka, Scott) Modified on 2/14/2024 (ceg). (Entered: 02/14/2024)
2/12/2024REDACTED VERSION of 259 Notice to Take Deposition by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(Czerwonka, Scott) (Entered: 02/12/2024)
2/9/2024Cross NOTICE of Subpoena Ad Testificandum to Alina Shipman by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Exhibit 1)(Czerwonka, Scott) (Entered: 02/09/2024)
2/6/2024 NOTICE of Subpoena Ad Testificandum to Zinc Health Services, LLC by Amgen Inc. (Attachments: # 1 Exhibit 1)(Hallowell, Taylor) (Entered: 02/06/2024)
2/6/2024SO ORDERED, re 243 Stipulation and Order to Extend Time to File Redacted Version of D.I. 259 to February 12, 2024. Ordered by Judge Jennifer L. Hall on 2/6/2024. (ceg) (Entered: 02/06/2024)
2/5/2024 NOTICE of Subpoena Duces Tecum to Dr. Michael Doyle by Amgen Inc. (Attachments: # 1 Exhibit 1)(Hallowell, Taylor) (Entered: 02/05/2024)
2/5/2024 STIPULATION and [Proposed] Order to Extend Time to File Public Redacted Version of D.I. 259 by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 02/05/2024)
2/5/2024NOTICE OF SERVICE of (1) Defendant's Objections and Responses to Plaintiff's Requests for Admission; (2) Defendant's Objections and Responses to Plaintiff's Second Set of Requests for Admission (30 - 35) filed by Amgen Inc..(Hallowell, Taylor) (Entered: 02/05/2024)
2/5/2024NOTICE OF SERVICE of (1) Plaintiff Regeneron Pharmaceuticals, Inc. Responses and Objections to Defendant Amgen Inc. First Set of Requests for Admission (Nos. 1-16) and (2) Plaintiff Regeneron Pharmaceuticals, Inc. Responses and Objections to Defendant Amgen Inc. Second Set of Requests for Admission (Nos. 17-35) filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 02/05/2024)
2/5/2024 NOTICE of Subpoena Duces Tecum and Ad Testificandum to Suzanne Shugg by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Czerwonka, Scott) (Entered: 02/05/2024)
2/1/2024 NOTICE of Subpoena Ad Testificandum to Dr. Michael Doyle by Amgen Inc. (Attachments: # 1 Exhibit 1)(Hallowell, Taylor) (Entered: 02/01/2024)
1/31/2024NOTICE to Take Deposition of Zinc Health Services on February 9, 2024 filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Czerwonka, Scott) (Entered: 01/31/2024)
1/29/2024[SEALED] NOTICE to Take Deposition of Amgen, Inc. on February 2, 2024 filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Czerwonka, Scott) (Entered: 01/29/2024)
1/26/2024NOTICE OF SERVICE of Plaintiff Regeneron Pharmaceuticals, Inc. Objections and Responses to Defendant Amgen Inc. Fourth Set of Interrogatories filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 01/26/2024)
1/26/2024NOTICE OF SERVICE of Plaintiff Regeneron Pharmaceuticals, Inc. First Supplemental Objections and Responses to Defendant Amgen Inc. First Set of Interrogatories No. 2 filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 01/26/2024)
1/26/2024NOTICE OF SERVICE of Defendant's Responses and Objections to Plaintiff's Fourth Set of Interrogatories filed by Amgen Inc..(Hallowell, Taylor) (Entered: 01/26/2024)
1/26/2024NOTICE to Take Deposition of Zinc Health Services on date, time, and location mutually agreed upon by the parties filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Certificate of Service)(Czerwonka, Scott) (Entered: 01/26/2024)
1/26/2024NOTICE to Take Deposition of CVS Health Corporation, CaremarkPCS Health LLC, CVS Caremark Part D Services LLC and Zinc Health Services on date, time, and location mutually agreed upon by the parties filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Certificate of Service)(Czerwonka, Scott) (Entered: 01/26/2024)
1/26/2024NOTICE to Take Deposition of CaremarkPCS Health LLC on date, time, and location mutually agreed upon by the parties filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Certificate of Service)(Czerwonka, Scott) (Entered: 01/26/2024)
1/26/2024 NOTICE of Subpoena Ad Testificandum to Suzanne Shugg by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Exhibit 1)(Czerwonka, Scott) (Entered: 01/26/2024)
1/25/2024NOTICE to Take Deposition of Robert A. Bradway on January 26, 2024 filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 01/25/2024)
1/24/2024NOTICE OF SERVICE of Defendant Amgen Inc.'s Amended Rule 26(a)(1) Disclosures filed by Amgen Inc..(Hallowell, Taylor) (Entered: 01/24/2024)
1/24/2024 NOTICE of Subpoena Ad Testificandum to Alina Shipman by Amgen Inc. (Attachments: # 1 Exhibit 1)(Hallowell, Taylor) (Entered: 01/24/2024)
1/24/2024 NOTICE of Subpoena Ad Testificandum to Dr. Michael Doyle by Amgen Inc. (Attachments: # 1 Exhibit 1)(Hallowell, Taylor) (Entered: 01/24/2024)
1/24/2024NOTICE to Take Deposition of Marion McCourt on January 30, 2024 filed by Amgen Inc..(Hallowell, Taylor) (Entered: 01/24/2024)
1/23/2024REDACTED VERSION of 218 Letter, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit C, # 3 Exhibit E, # 4 Exhibit F)(Wilks, David) (Entered: 01/23/2024)
1/18/2024REDACTED VERSION of 237 Notice (Other) by Amgen Inc.. (Hallowell, Taylor) (Entered: 01/18/2024)
1/17/2024SO ORDERED, re 243 Stipulation and Order to Extend Time to File Redacted Version of D.I. 218 to January 23, 2024. Ordered by Judge Jennifer L. Hall on 1/17/2024. (ceg) (Entered: 01/17/2024)
1/16/2024 NOTICE of Subpoena Ad Testificandum to Express Scripts, Inc., Express Scripts Senior Care Holdings, Inc., Ascent Health Services LLC, and Cigna Corp. by Amgen Inc. (Attachments: # 1 Exhibit 1)(Hallowell, Taylor) (Entered: 01/16/2024)
1/16/2024 STIPULATION and [Proposed] Order to Extend Time to File Redacted Version of D.I. 218 to January 23, 2024 by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 01/16/2024)
1/16/2024REDACTED VERSION of 217 Letter, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1-13)(Czerwonka, Scott) (Entered: 01/16/2024)
1/16/2024REDACTED VERSION of 213 Letter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-H, # 2 Exhibit M-Q)(Czerwonka, Scott) (Entered: 01/16/2024)
1/16/2024REDACTED VERSION of 214 Letter, by Amgen Inc.. (Hallowell, Taylor) (Entered: 01/16/2024)
1/12/2024NOTICE to Take Deposition of Express Scripts, Inc., Express Scripts Senior Care Holdings, Inc., Ascent Health Services LLC, and Cigna Corp. on January 25, 2024 filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Certificate of Service)(Czerwonka, Scott) (Entered: 01/12/2024)
1/12/2024NOTICE to Take Deposition of Murdo Gordon on January 19, 2024 filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 01/12/2024)
1/11/2024[SEALED] Amended NOTICE of Rule 30(b)(6) Deposition to Plaintiff Regeneron Pharmaceuticals, Inc. by Amgen Inc. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 01/11/2024)
1/11/2024NOTICE to Take Deposition of Swaminathan Subramanian on January 18, 2024 filed by Amgen Inc..(Hallowell, Taylor) (Entered: 01/11/2024)
1/11/2024NOTICE to Take Deposition of Richard O'Neal on January 18, 2024 filed by Amgen Inc..(Hallowell, Taylor) (Entered: 01/11/2024)
1/11/2024NOTICE to Take Deposition of Scott Cullins on January 17, 2024 filed by Amgen Inc..(Hallowell, Taylor) (Entered: 01/11/2024)
1/11/2024NOTICE to Take Deposition of Leo (Ed) Kirk on January 12, 2024 filed by Amgen Inc..(Hallowell, Taylor) (Entered: 01/11/2024)
1/8/2024SO ORDERED, 232 Stipulation and Order to Extend Time to File Redacted Versions of D.I. 213, D.I. 214, D.I. 217, and D.I. 218 to January 16, 2024.. Ordered by Judge Jennifer L. Hall on 1/8/2024. (ceg) (Entered: 01/08/2024)
1/8/2024Amended STIPULATION and [Proposed] Order to Extend Time to File Redacted Versions by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) (Entered: 01/08/2024)
1/8/2024 NOTICE of Subpoena Ad Testificandum to Amy Bricker by Amgen Inc. (Attachments: # 1 Exhibit 1)(Hallowell, Taylor) (Entered: 01/08/2024)
1/5/2024Case Reassigned to Judge Jennifer L Hall. Please include the initials of the Judge (JLH) after the case number on all documents filed., Case no longer referred to Magistrate Judge. (rjb) (Entered: 01/05/2024)
1/4/2024NOTICE to Take Deposition of John Ryan on January 9, 2024 filed by Amgen Inc..(Hallowell, Taylor) (Entered: 01/04/2024)
1/4/2024229
  • Order
ORAL ORDER: IT IS HEREBY ORDERED that the transcript of the January 4, 2024 discovery dispute teleconference shall serve as the Order of the Court. Ordered by Judge Jennifer L. Hall on 1/4/2024. (ceg) (Entered: 01/04/2024)
1/4/2024Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute Teleconference held on 1/4/2024. (*Court Reporter Stacy Ingram.) (ceg) (Entered: 01/04/2024)
1/4/2024228
  • Order
ORAL ORDER: This case is reassigned to Judge Jennifer L. Hall. A formal CM/ECF reassignment will be done in the near future. Ordered by Chief Judge Colm F. Connolly on 1/4/2024. (nms) (Entered: 01/04/2024)
1/3/2024NOTICE OF SERVICE of Plaintiff Regeneron Pharmaceuticals, Inc. Rule 26(a)(1)(A)Disclosures filed by Regeneron Pharmaceuticals, Inc..(Wilks, David) (Entered: 01/03/2024)
1/2/2024 NOTICE of Subpoena Ad Testificandum directed to Amy Bricker by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Exhibit 1)(Czerwonka, Scott) (Entered: 01/02/2024)
12/28/2023 NOTICE of Subpoena Ad Testificandum to OptumRx, Inc. and UnitedHealthcare, Inc. by Amgen Inc. (Attachments: # 1 Exhibit 1)(Hallowell, Taylor) (Entered: 12/28/2023)
12/27/2023NOTICE OF SERVICE of (1) Defendant Amgen Inc.'s Second Set of Requests for Admission to Plaintiff Regeneron Pharmaceuticals, Inc.; (2) Defendant Amgen Inc.'s Fourth Set of Interrogatories to Plaintiff Regeneron Pharmaceuticals, Inc. filed by Amgen Inc..(Hallowell, Taylor) (Entered: 12/27/2023)
12/27/2023NOTICE OF SERVICE of (1) Plaintiff Regeneron Pharmaceuticals, Inc.'s Second Set of Requests for Admission; and (2) Plaintiff Regeneron Pharmaceuticals, Inc.'s Fourth Set of Interrogatories filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 12/27/2023)
12/27/2023NOTICE OF SERVICE of Plaintiff Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Defendant Amgen Inc.'s Third Set of Interrogatories filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 12/27/2023)
12/26/2023SO ORDERED, 221 Stipulation and Order to Extend Time to File Redacted Versions of D.I. 213, D.I. 214, D.I. 217, and D.I. 218 to January 8, 2024. Ordered by Judge Jennifer L. Hall on 12/26/2023. (ceg) (Entered: 12/26/2023)
12/26/2023 STIPULATION and Proposed Order to Extend Time to File Redacted Versions of D.I. 213, D.I. 214, D.I. 217, and D.I. 218 to January 8, 2024 - filed by Amgen Inc.. (Hallowell, Taylor) Modified on 12/28/2023 (nms). (Entered: 12/26/2023)
12/21/2023NOTICE OF SERVICE of Defendant's Responses and Objections to Plaintiff's Third Set of Interrogatories (Nos. 9 - 21) Served on November 21, 2023 filed by Amgen Inc..(Hallowell, Taylor) (Entered: 12/21/2023)
12/21/2023 EXHIBITS to 218 Letter, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit B, # 2 Exhibit D, # 3 Exhibit G)(Wilks, David) Modified on 12/22/2023 (nms). (Entered: 12/21/2023)
12/21/2023[SEALED] Letter to The Honorable Jennifer L. Hall, from David E. Wilks, regarding discovery dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit C, # 3 Exhibit E, # 4 Exhibit F, # 5 Certificate of Service)(Wilks, David) Modified on 12/22/2023 (nms). (Entered: 12/21/2023)
12/21/2023[SEALED] Letter to the Honorable Jennifer L. Hall, from Melanie K. Sharp, regarding discovery dispute. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Certificate of Service)(Sharp, Melanie) Modified on 12/22/2023 (nms). (Entered: 12/21/2023)
12/19/2023
  • Motion
PROPOSED Order to 213 Letter, by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) Modified on 12/19/2023 (nms). (Entered: 12/19/2023)
12/19/2023 EXHIBITS I-L to 213 Letter, by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) Modified on 12/19/2023 (nms). (Entered: 12/19/2023)
12/19/2023[SEALED] Letter to the Honorable Jennifer L. Hall from Melanie K. Sharp regarding Discovery Dispute. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A, # 3 Exhibit B, # 4 Exhibit C, # 5 Exhibit D, # 6 Exhibit E, # 7 Exhibit F, # 8 Exhibit G, # 9 Exhibit H, # 10 Exhibit I, # 11 Exhibit J, # 12 Certificate of Service)(Sharp, Melanie) (Entered: 12/19/2023)
12/19/2023[SEALED] Letter to The Honorable Jennifer L. Hall from Scott B.Czerwonka regarding Discovery Dispute. (Attachments: # 1 Exhibit A-H, # 2 Exhibit M-Q, # 3 Certificate of Service)(Czerwonka, Scott) (Entered: 12/19/2023)
12/19/2023NOTICE to Take Deposition of Amy Bricker on January 11, 2024 filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 12/19/2023)
12/15/2023211
  • Order
ORAL ORDER Setting Teleconference: The Court has reviewed the Motion for Teleconference to Resolve Discovery Disputes (D.I. 210 ). The Court's schedule does not permit a teleconference on December 18, 20, or 21. A discovery dispute teleconference is scheduled for January 4, 2024 at 3:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than December 19, 2023, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than December 21, 2023, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Ordered by Judge Jennifer L. Hall on 12/15/2023. (ceg) (Entered: 12/15/2023)
12/14/2023
  • Order
SO ORDERED, 205 Stipulation and Order to Amend the Case Scheduling Order (D.I. 67). (*Reset Scheduling Order Deadlines: Fact Discovery completed by 1/26/2024; Opening Expert Reports due by 2/13/2024; Rebuttal Expert Reports due by 3/29/2024; Reply Expert Reports due by 4/15/2024; Expert Discovery due by 5/3/2024; Summary Judgment Motions due by 5/22/2024; Answering Brief due 6/21/2024; Reply Brief due 7/12/2024; Daubert Motions due by 5/28/2024; Answering Brief due 6/25/2024; Reply Brief due 7/15/2024 ). Ordered by Judge Jennifer L. Hall on 12/14/2023. (ceg) (Entered: 12/14/2023)
12/13/2023
  • Motionby Π
MOTION for Teleconference to Resolve Discovery Disputes - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Czerwonka, Scott) (Entered: 12/13/2023)
12/13/2023REDACTED VERSION of 203 Notice to Take Deposition by Amgen Inc.. (Hallowell, Taylor) (Entered: 12/13/2023)
12/12/2023 NOTICE of Deposition of Andy Chiu on December 19, 2023 by Regeneron Pharmaceuticals, Inc. (Czerwonka, Scott) (Entered: 12/12/2023)
12/12/2023
  • Motion to Appear Pro Hac Vice
SO ORDERED, 207 Motion for Pro Hac Vice Appearance of Attorney Leesa Haspel filed by Amgen Inc. Ordered by Judge Jennifer L. Hall on 12/12/2023. (ceg) (Entered: 12/12/2023)
12/11/2023
  • Motion to Appear Pro Hac Viceby Δ
MOTION for Pro Hac Vice Appearance of Attorney Leesa Haspel - filed by Amgen Inc.. Motions referred to Jennifer L. Hall.(Hallowell, Taylor) (Entered: 12/11/2023)
12/11/2023
  • Motion to Appear Pro Hac Vice
SO ORDERED, 204 Motion for Pro Hac Vice Appearance of Attorney William Cooke, and 206 Motion for Pro Hac Vice Appearance of Attorney Naz Akyol filed by Regeneron Pharmaceuticals, Inc. Ordered by Judge Jennifer L. Hall on 12/11/2023. (ceg) (Entered: 12/11/2023)
12/11/2023
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Naz Akyol - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 12/11/2023)
12/8/2023
  • Motion
STIPULATION and [Proposed] Order to Amend the Case Scheduling Order (D.I. 67), by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(Wilks, David) Modified on 12/11/2023 (nms). (Entered: 12/08/2023)
12/8/2023
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney William Cooke - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 12/08/2023)
12/6/2023[SEALED] NOTICE to Take Deposition of Regeneron Pharmaceuticals, Inc. on date, time, and location mutually agreed upon by the parties filed by Amgen Inc. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 12/7/2023 (ceg). (Entered: 12/06/2023)
12/1/2023Official Transcript of Discovery Dispute Teleconference held on 11/13/2023 before Judge Jennifer L. Hall. Court Reporter/Transcriber Bonnie Archer, Email: Bonnie_Archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 12/26/2023. Redacted Transcript Deadline set for 1/2/2024. Release of Transcript Restriction set for 2/29/2024. (ceg) (Entered: 12/01/2023)
12/1/2023NOTICE OF SERVICE of Plaintiff Regeneron Pharmaceuticals, Inc. Responses and Objections to Defendant Amgen Inc. Second Set of Interrogatories filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 12/01/2023)
12/1/2023AMENDED Notice of Rule 30(b)(6) Deposition of OptumRx, Inc. and UnitedHealthcare, Inc. on January 8, 2024 by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 12/4/2023 (nms). (Entered: 12/01/2023)
12/1/2023NOTICE OF SERVICE of (1) Defendant Amgen Inc.s Requests for Admission to Plaintiff Regeneron Pharmaceuticals, Inc.; and (2) Defendant Amgen Inc.s Third Set of Interrogatories to Plaintiff Regeneron Pharmaceuticals, Inc. filed by Amgen Inc..(Hallowell, Taylor) (Entered: 12/01/2023)
11/29/2023REDACTED VERSION of 187 Declaration by Amgen Inc.. (Hallowell, Taylor) (Entered: 11/29/2023)
11/29/2023REDACTED VERSION of 186 Letter, by Amgen Inc.. (Attachments: # 1 Exhibits A-C)(Hallowell, Taylor) Modified on 11/30/2023 (nms). (Entered: 11/29/2023)
11/29/2023REDACTED VERSION of 183 Letter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Wilks, David) (Entered: 11/29/2023)
11/29/2023NOTICE to Take Deposition of OptumRx and UnitedHealthcare, Inc. on December 13, 2023 filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Czerwonka, Scott) (Entered: 11/29/2023)
11/21/2023NOTICE OF SERVICE of Plaintiff Regeneron Pharmaceuticals, Inc. Requests for Admission to Defendant Amgen Inc. filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 11/21/2023)
11/21/2023NOTICE OF SERVICE of Plaintiff Regeneron Pharmaceuticals, Inc. Third Set of Interrogatories to Defendant Amgen Inc. (Nos. 9-21) filed by Regeneron Pharmaceuticals, Inc..(Wilks, David) (Entered: 11/21/2023)
11/17/2023 NOTICE of Deposition of Jasper van Grunsven on December 11, 2023 by Regeneron Pharmaceuticals, Inc. (Czerwonka, Scott) (Entered: 11/17/2023)
11/17/2023 NOTICE of Deposition of Jennifer Norton on December 21, 2023 by Regeneron Pharmaceuticals, Inc. (Czerwonka, Scott) (Entered: 11/17/2023)
11/17/2023 NOTICE of Deposition of David Zimmer on December 19, 2023 by Regeneron Pharmaceuticals, Inc. (Czerwonka, Scott) (Entered: 11/17/2023)
11/15/2023SO ORDERED, 189 Stipulation and Order to Extend Time to file Public Redacted Versions of D.I. 183, D.I. 186, and D.I. 187 to November 29, 2023. Ordered by Judge Jennifer L. Hall on 11/15/2023. (ceg) (Entered: 11/15/2023)
11/14/2023 STIPULATION and Proposed Order to Extend Time to file Public Redacted Versions of D.I. 183, D.I. 186, and D.I. 187 to November 29, 2023 - filed by Amgen Inc.. (Hallowell, Taylor) Modified on 11/15/2023 (nms). (Entered: 11/14/2023)
11/13/2023188
  • OrderDenied
ORAL ORDER: Regeneron's Discovery Motion (D.I. 181 ) is DENIED without prejudice to renew as stated at today's teleconference. Ordered by Judge Jennifer L. Hall on 11/13/2023. (ceg) (Entered: 11/13/2023)
11/13/2023Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute Teleconference held on 11/13/2023. (*Court Reporter Bonnie Archer.) (ceg) (Entered: 11/13/2023)
11/9/2023[SEALED] DECLARATION of Kave Niksefat re 186 Letter, by Amgen Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 11/9/2023 (nms). (Entered: 11/09/2023)
11/9/2023[SEALED] Letter to the Honorable Jennifer L. Hall, from Melanie K. Sharp, regarding redaction dispute (D.I. 183 ). (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Certificate of Service)(Sharp, Melanie) Modified on 11/9/2023 (nms). (Entered: 11/09/2023)
11/7/2023
  • Motion
PROPOSED Order to 183 Letter, by Regeneron Pharmaceuticals, Inc.. (Wilks, David) Modified on 11/8/2023 (nms). (Entered: 11/07/2023)
11/7/2023 EXHIBIT C to 183 Letter, by Regeneron Pharmaceuticals, Inc.. (Wilks, David) Modified on 11/8/2023 (nms). (Entered: 11/07/2023)
11/7/2023[SEALED] Letter to The Honorable Jennifer L. Hall, from David E. Wilks, regarding redaction dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Certificate of Service)(Wilks, David) Modified on 11/8/2023 (nms). (Entered: 11/07/2023)
11/6/2023182
  • Order
ORAL ORDER Setting Teleconference: The Court has reviewed the Motion for Teleconference to Resolve Redactions Dispute (D.I. 181 ). A discovery dispute teleconference is scheduled for November 13, 2023 at 3:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than November 7, 2023, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than November 9, 2023, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Ordered by Judge Jennifer L. Hall on 11/6/2023. (ceg) (Entered: 11/06/2023)
11/2/2023
  • Motionby Π
MOTION for Teleconference to Resolve Redactions Dispute - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 11/02/2023)
11/2/2023NOTICE OF SERVICE of Defendant Amgen Inc.'s Second Set of Interrogatories to Plaintiff Regeneron Pharmaceuticals, Inc. filed by Amgen Inc..(Hallowell, Taylor) (Entered: 11/02/2023)
10/25/2023REDACTED VERSION of 169 Letter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-L)(Wilks, David) (Entered: 10/25/2023)
10/25/2023REDACTED VERSION of 171 Letter, by Amgen Inc.. (Hallowell, Taylor) (Entered: 10/25/2023)
10/24/2023CORRECTING ENTRY: The pdf for the exhibits found at D.I. 141 have been replaced per counsel's request and opposing counsel's approval. Exhibit M has been amended. (nms) (Entered: 10/24/2023)
10/20/2023NOTICE OF SERVICE of Plaintiff Regeneron Pharmaceuticals, Inc. Responses and Objections to Defendant Amgen Inc. Third Set of Requests for Production of Documents filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 10/20/2023)
10/19/2023SO ORDERED, 175 Stipulation and Order to Extend Time to submit redacted versions of D.I. 169 and D.I. 171 to October 25, 2023. Ordered by Judge Jennifer L. Hall on 10/19/2023. (ceg) (Entered: 10/19/2023)
10/17/2023REDACTED VERSION of 167 Letter, by Ascent Health Services LLC, CIGNA Corporation, Express Scripts Senior Care Holdings, Inc., Express Scripts, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Silverstein, Alan) Modified on 10/17/2023 (nms). (Entered: 10/17/2023)
10/17/2023 STIPULATION and Proposed Order to Extend Time to submit redacted versions of D.I. 169 and D.I. 171 to October 25, 2023 - filed by Amgen Inc.. (Hallowell, Taylor) Modified on 10/17/2023 (nms). (Entered: 10/17/2023)
10/16/2023174
  • OrderGranted
ORAL ORDER: Regeneron's discovery motion (D.I. 164 ) is GRANTED as stated at today's teleconference. Ordered by Judge Jennifer L. Hall on 10/16/2023. (ceg) (Entered: 10/16/2023)
10/16/2023Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute Teleconference held on 10/16/2023. (*Court Reporter Stacy Ingram, Hawkins Reporting Service.) (ceg) (Entered: 10/16/2023)
10/13/2023
  • Answer
ANSWER to 148 Answer to Amended Complaint, and Counterclaims, by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) Modified on 10/13/2023 (nms). (Entered: 10/13/2023)
10/13/2023REDACTED VERSION of 160 Letter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit B)(Wilks, David) (Entered: 10/13/2023)
10/13/2023[SEALED] Letter to the Honorable Jennifer L. Hall, from Melanie K. Sharp, regarding discovery dispute. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Certificate of Service)(Sharp, Melanie) Modified on 10/13/2023 (nms). (Entered: 10/13/2023)
10/13/2023Pro Hac Vice Attorneys Ben A. Sherwood and Stephen Weissman for Amgen Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 10/13/2023)
10/11/2023
  • Motion
PROPOSED Order to 169 Letter, by Regeneron Pharmaceuticals, Inc.. (Wilks, David) Modified on 10/11/2023 (nms). (Entered: 10/11/2023)
10/11/2023[SEALED] Letter to The Honorable Jennifer L. Hall, from David E. Wilks, regarding discovery dispute. (Attachments: # 1 Exhibits A-L, # 2 Certificate of Service)(Wilks, David) Modified on 10/11/2023 (nms). (Entered: 10/11/2023)
10/11/2023168
  • Order
ORAL ORDER: Having reviewed Plaintiff's and non-party ESI's discovery dispute letters (D.I. 157 , 160 , 167 ), the Court provides the following guidance: (1) The Court's prior order contemplated that Plaintiff would bear the costs of ESI's compliance, which the Court understood to include attorney review for responsiveness/privilege. (2) The Court's prior order assumed that Plaintiff could and would propose new search terms if it didn't want to pay ESI's costs to review the hits. (3) ESI needs to work with Plaintiff to give it an idea about whether the proposed search terms are hitting on a substantial number of non-responsive documents so that Plaintiff can modify its proposed terms accordingly. (4) The Court has questions about whether ESI's current estimate of $90-100K for attorney review is excessive in light of the number of hits and the number of document requests. (5) The parties should meet and confer again. (6) The parties can re-engage the Court if they can't work it out in view of this guidance; the Court may shift the costs of the next conference to the side that is not substantially justified. (7) The discovery dispute conference scheduled for today is CANCELLED. Ordered by Judge Jennifer L. Hall on 10/11/2023. (ceg) (Entered: 10/11/2023)
10/10/2023[SEALED] Letter to The Honorable Jennifer L. Hall, from Alan R. Silverstein, Esq., regarding discovery dispute (D.I. 157 , 130 , 128 ). (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Silverstein, Alan) Modified on 10/11/2023 (nms). (Entered: 10/10/2023)
10/10/2023NOTICE OF SERVICE of Plaintiff Regeneron Pharmaceuticals, Inc. Objections and Responses to Defendant Amgen Inc. Second Set of Requests for Production of Documents filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 10/10/2023)
10/10/2023165
  • Order
ORAL ORDER Setting Teleconference: The Court has reviewed the Motion for Teleconference to Resolve Discovery Dispute (D.I. 164 ). A discovery dispute teleconference is scheduled for October 16, 2023 at 1:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than October 11, 2023, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than October 13, 2023 at noon, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Ordered by Judge Jennifer L. Hall on 10/10/2023. (ceg) (Entered: 10/10/2023)
10/10/2023
  • Motion to Extend Time
SO ORDERED, 163 Stipulation and Order to Extend Time to Answer, Move or Otherwise Respond to Counterclaim is extended to and including October 13, 2023. Ordered by Judge Jennifer L. Hall on 10/10/2023. (ceg) (Entered: 10/10/2023)
10/10/2023
  • Motionby Π
MOTION for Teleconference to Resolve Discovery Dispute - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 10/10/2023)
10/6/2023 STIPULATION and Proposed Order to Extend Time to Answer, Move or Otherwise Respond to Counterclaim is extended to and including October 13, 2023, by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) Modified on 10/8/2023 (nms). (Entered: 10/06/2023)
10/6/2023CORRECTING ENTRY: The pdf for D.I. 161 has been replaced with a corrected version. The caption has been amended. The NEF for the filing has been regenerated. (nms) (Entered: 10/06/2023)
10/6/2023
  • Motion
PROPOSED Order to 160 Letter, by Regeneron Pharmaceuticals, Inc.. (Wilks, David) Modified on 10/6/2023 (nms). (Entered: 10/06/2023)
10/6/2023 EXHIBIT A to 160 Letter, by Regeneron Pharmaceuticals, Inc.. (Wilks, David) Modified on 10/6/2023 (nms). (Main Document 161 replaced on 10/6/2023) (nms). (Entered: 10/06/2023)
10/6/2023[SEALED] Letter to The Honorable Jennifer L. Hall from David E. Wilks regarding Discovery Dispute. (Attachments: # 1 Exhibit B, # 2 Certificate of Service)(Wilks, David) (Entered: 10/06/2023)
10/6/2023159
  • Motion to FileDenied
ORAL ORDER: Amgen's Motion for Leave to File Motion for Summary Judgment and to Stay Discovery (D.I. 135) is DENIED. The Court's Scheduling Order provides that if "leave to file [an early motion for summary judgment] is granted, Amgen may not file, without first seeking leave from the Court to file, any additional motion for summary judgment." (D.I. 67, para. 11(a).) In its pending motion, "Amgen now respectfully seeks leave only if the Court finds it appropriate to confirm that if any portion of the case survives early summary judgment, Amgen could still bring a later motion for summary judgment." (D.I. 136 at 2.) The Court does not find it appropriate to so confirm. Ordered by Judge Jennifer L. Hall on 10/6/2023. (JLH) (Entered: 10/06/2023)
10/5/2023158
  • Order
ORAL ORDER Setting Teleconference: The Court has reviewed the Motion for Teleconference to Resolve Discovery Dispute (D.I. 157 ). A discovery dispute teleconference is scheduled for October 11, 2023 at 4:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than October 6, 2023, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than October 10, 2023, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Ordered by Judge Jennifer L. Hall on 10/5/2023. (ceg) (Entered: 10/05/2023)
10/4/2023
  • Motionby Π
MOTION for Teleconference to Resolve Discovery Dispute - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Czerwonka, Scott) (Entered: 10/04/2023)
10/4/2023REDACTED VERSION of 148 Answer to Amended Complaint,, Counterclaim, by Amgen Inc.. (Hallowell, Taylor) (Entered: 10/04/2023)
9/29/2023SO ORDERED, 155 Stipulation and Order to Extend Time to submit a public redacted version of D.I. 148 to October 4, 2023. Ordered by Judge Jennifer L. Hall on 9/29/2023. (ceg) (Entered: 09/29/2023)
9/27/2023 STIPULATION and Proposed Order to Extend Time to submit a public redacted version of D.I. 148 to October 4, 2023 - filed by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) Modified on 9/27/2023 (nms). (Entered: 09/27/2023)
9/21/2023REDACTED VERSION of 141 Letter, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A - BB)(Czerwonka, Scott) (Entered: 09/21/2023)
9/21/2023NOTICE OF SERVICE of Defendant Amgen Inc.'s Third Set of Requests for the Production of Documents from Plaintiff Regeneron Pharmaceuticals, Inc. filed by Amgen Inc..(Hallowell, Taylor) (Entered: 09/21/2023)
9/21/2023 NOTICE of Non-Party Subpoena Duces Tecum to Sanofi-Aventis U.S. LLC by Amgen Inc. (Hallowell, Taylor) (Entered: 09/21/2023)
9/21/2023 NOTICE of Non-Party Subpoena Duces Tecum to Sanofi US Services Inc. by Amgen Inc. (Hallowell, Taylor) (Entered: 09/21/2023)
9/21/2023 NOTICE of Non-Party Subpoena Duces Tecum to Sanofi SA by Amgen Inc. (Hallowell, Taylor) (Entered: 09/21/2023)
9/21/2023 NOTICE of Non-Party Subpoena Duces Tecum to Sanofi Biotechnology SAS by Amgen Inc. (Hallowell, Taylor) (Entered: 09/21/2023)
9/20/2023
  • Answer
[SEALED] ANSWER to 124 Amended Complaint with jury demand, and COUNTERCLAIMS against Regeneron Pharmaceuticals, Inc., by Amgen Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Certificate of Service)(Sharp, Melanie) Modified on 9/20/2023 (nms). (Entered: 09/20/2023)
9/18/2023REDACTED VERSION of 144 Letter, by Ascent Health Services LLC, CIGNA Corporation, Express Scripts Senior Care Holdings, Inc., Express Scripts, Inc.. (Attachments: # 1 Exhibit 1)(Silverstein, Alan) Modified on 9/19/2023 (nms). (Entered: 09/18/2023)
9/18/2023SO ORDERED, 146 Stipulation and Order to Extend Time to submit a redacted version of D.I. 141 to September 21, 2023. Ordered by Judge Jennifer L. Hall on 9/18/2023. (ceg) (Entered: 09/18/2023)
9/15/2023 STIPULATION and Proposed Order to Extend Time to Submit a redacted version of D.I. 141 to September 21, 2023 - filed by Amgen Inc.. (Hallowell, Taylor) Modified on 9/15/2023 (nms). (Entered: 09/15/2023)
9/13/2023145
  • OrderGranted
ORAL ORDER: Regeneron's discovery motion (D.I. 128 ) is GRANTED-IN-PART as stated at today's teleconference. Ordered by Judge Jennifer L. Hall on 9/13/2023. (ceg) (Entered: 09/13/2023)
9/13/2023Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute Teleconference held on 9/13/2023. (*Court Reporter Stacy Ingram, Hawkins Reporting Service.) (ceg) (Entered: 09/13/2023)
9/12/2023Pro Hac Vice Attorneys Kyle P. Seelbach and Bola Adeniran for Ascent Health Services LLC, CIGNA Corporation, Express Scripts Senior Care Holdings, Inc., and Express Scripts, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 09/12/2023)
9/11/2023[SEALED] Letter to The Honorable Jennifer L. Hall, from Alan R. Silverstein, regarding discovery dispute. (Attachments: # 1 Exhibit 1)(Silverstein, Alan) Modified on 9/12/2023 (ceg). (Entered: 09/11/2023)
9/11/2023REDACTED VERSION of 136 Letter,, by Amgen Inc.. (Attachments: # 1 Exhibit 1 - 15)(Sharp, Melanie) (Entered: 09/11/2023)
9/8/2023SO ORDERED, 138 Stipulation and Order to Extend Time to Submit Public Redacted Versions of D.I. 130 to September 8, 2023, and D.I. 136 to September 11, 2023. Ordered by Judge Jennifer L. Hall on 9/8/2023. (ceg) (Entered: 09/08/2023)
9/8/2023
  • Motion to File
RESPONSE to 7.1.1 Certification re 135 MOTION for Leave to File Motion for Summary Judgment and to Stay Discovery, filed by Regeneron Pharmaceuticals, Inc.. (Czerwonka, Scott) Modified on 9/8/2023 (nms). (Entered: 09/08/2023)
9/8/2023[SEALED] Letter to The Honorable Jennifer L. Hall, from David E. Wilks, regarding opposition to Motion for Leave to File Summary Judgment and Stay Discovery (D.I. 135 ). (Attachments: # 1 Exhibits A-BB, # 2 Certificate of Service)(Wilks, David) Modified on 9/8/2023 (nms). (Attachment 1 replaced on 10/24/2023) (nms). (Entered: 09/08/2023)
9/8/2023REDACTED VERSION of 130 Letter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A - N)(Czerwonka, Scott) (Entered: 09/08/2023)
9/8/2023NOTICE OF SERVICE of Defendant Amgen Inc.'s Second Set of Requests for the Production of Documents from Plaintiff Regeneron Pharmaceuticals, Inc. filed by Amgen Inc..(Hallowell, Taylor) (Entered: 09/08/2023)
9/6/2023 STIPULATION and [Proposed] Order to Extend Time to Submit Public Redacted Versions of D.I. 130 and D.I. 136 by Regeneron Pharmaceuticals, Inc. (Wilks, David) Modified on 9/7/2023 (ceg). (Entered: 09/06/2023)
9/5/2023137
  • Order
ORAL ORDER Setting Teleconference: The Court has reviewed the Motion for Teleconference to Resolve Discovery Disputes (D.I. 128 ). A discovery dispute teleconference is scheduled for September 13, 2023 at 3:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than September 11, 2023, non-parties Express Scripts, Inc., Express Scripts Senior Care Holdings, Inc., Cigna Corporation, and Ascent Health Services LLC may file a letter, not to exceed three pages, in no less than 12-point font, outlining its reasons for its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Regeneron shall serve a copy of the Court's oral order on the third parties by noon tomorrow. Ordered by Judge Jennifer L. Hall on 9/5/2023. (ceg) (Entered: 09/05/2023)
9/5/2023
  • Motion to Appear Pro Hac Vice
SO ORDERED, 134 MOTION for Pro Hac Vice Appearance of Attorney Kyle P. Seelbach and Omobolanle Adeniran filed by Express Scripts Senior Care Holdings, Inc., Express Scripts, Inc., CIGNA Corporation, Ascent Health Services LLC. Ordered by Judge Jennifer L. Hall on 9/5/2023. (ceg) (Entered: 09/05/2023)
8/31/2023[SEALED] Letter to the Honorable Jennifer L. Hall, from Melanie K. Sharp, in support of motion for leave to file motion for summary judgment and to stay discovery (D.I. 135 ). (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Certificate of Service)(Sharp, Melanie) Modified on 9/1/2023 (nms). (Entered: 08/31/2023)
8/31/2023
  • Motion to File
MOTION for Leave to File Motion for Summary Judgment and to Stay Discovery - filed by Amgen Inc.. (Attachments: # 1 7.1.1 Certification, # 2 Proposed Order) Motions referred to Jennifer L. Hall.(Sharp, Melanie) Modified on 8/31/2023 (nms). (Entered: 08/31/2023)
8/31/2023
  • Motion to Appear Pro Hac Viceby Δ
MOTION for Pro Hac Vice Appearance of Attorney Kyle P. Seelbach and Omobolanle Adeniran - filed by Ascent Health Services LLC, CIGNA Corporation, Express Scripts Senior Care Holdings, Inc., Express Scripts, Inc.. Motions referred to Jennifer L. Hall.(Barry, Sara) (Entered: 08/31/2023)
8/31/2023NOTICE of Appearance by Sara Barry on behalf of Ascent Health Services LLC, CIGNA Corporation, Express Scripts Senior Care Holdings, Inc., Express Scripts, Inc. (Barry, Sara) (Entered: 08/31/2023)
8/31/2023NOTICE of Appearance by Alan Richard Silverstein on behalf of Express Scripts, Inc., Express Scripts Senior Care Holdings, Inc., CIGNA Corporation, Ascent Health Services LLC (Silverstein, Alan) (Entered: 08/31/2023)
8/30/2023
  • Motion
PROPOSED Order for 130 Letter, by Regeneron Pharmaceuticals, Inc.. (Wilks, David) Modified on 8/30/2023 (nms). (Entered: 08/30/2023)
8/30/2023[SEALED] Letter to The Honorable Jennifer L. Hall, from David E. Wilks, regarding discovery dispute. (Attachments: # 1 Exhibits A-N, # 2 Certificate of Service)(Wilks, David) Modified on 8/30/2023 (nms). (Entered: 08/30/2023)
8/30/2023REDACTED VERSION of 122 Exhibit to a Document by Regeneron Pharmaceuticals, Inc.. (Wilks, David) (Entered: 08/30/2023)
8/30/2023
  • Motionby Π
MOTION for Teleconference to Resolve Discovery Disputes - filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibits A-B)Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 08/30/2023)
8/30/2023CORRECTING ENTRY: The link and reference to D.I. 122 at D.I. 125 has been removed. Multiple redacted documents cannot be coupled together but need to be filed independent of each other. Counsel is to refile a redacted version of the sealed filing at D.I. 122 . (nms) (Entered: 08/30/2023)
8/30/2023 Letter to the Honorable Jennifer L. Hall, from Melanie K. Sharp, regarding response to letter (D.I. 126 ). (Sharp, Melanie) Modified on 8/30/2023 (nms). (Entered: 08/30/2023)
8/29/2023 Letter to The Honorable Jennifer L. Hall, from David E. Wilks, regarding the Courts August 28, 2023 Oral Order and the filing of redacted versions of Regenerons Amended Complaint and supporting exhibits. (Wilks, David) Modified on 8/29/2023 (nms). (Entered: 08/29/2023)
8/29/2023REDACTED VERSION of 124 Amended Complaint, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibits 1-23, # 2 Redline version) (Wilks, David) Modified on 8/30/2023 (nms). (Entered: 08/29/2023)
8/28/2023
  • Complaint
[SEALED] AMENDED COMPLAINT against Amgen Inc. - filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibits 1-23, # 2 Redline version, # 3 Certificate of Service)(Wilks, David) Modified on 8/29/2023 (nms). (Entered: 08/28/2023)
8/28/2023123
  • Order
ORAL ORDER: The parties' stipulation at D.I. 121 is SO ORDERED. Regeneron must file a redacted version within 7 days of filing its Amended Complaint (and exhibits) under seal. Should the Court have questions about the amount redacted, the proponent of keeping those portions under seal will be asked for a declaration explaining in detail why disclosure of any proposed sealed or redacted material would "work a clearly defined and serious injury to the party seeking closure." See In re Avandia Mktg., Sales Practices & Prods. Liab. Litig., 924 F.3d 662, 672 (3d Cir. 2019) (quoting Miller v. Indiana Hosp., 16 F.3d 549, 551 (3d Cir. 1994) (internal quotation marks omitted)). Ordered by Judge Jennifer L. Hall on 08/28/2023. (smg) (Entered: 08/28/2023)
8/22/2023[SEALED] Exhibits A-C to 121 Stipulation, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Certificate of Service)(Wilks, David) Modified on 8/22/2023 (nms). (Entered: 08/22/2023)
8/22/2023
  • Motionby Π
STIPULATION and [Proposed] Order Regarding Amended Complaint by Regeneron Pharmaceuticals, Inc.. (Wilks, David) (Entered: 08/22/2023)
8/8/2023NOTICE to Take Deposition of Steven Hyde on August 10, 2023 filed by Amgen Inc..(Higgins, James) (Entered: 08/08/2023)
8/4/2023NOTICE OF SERVICE of (1) Defendant's Responses and Objections to Plaintiff's Third Set of Interrogatories (No. 9); (2) Defendant's Responses and Objections to Plaintiff's Third Set of Requests for Production (Nos. 12 - 17) filed by Amgen Inc..(Hallowell, Taylor) (Entered: 08/04/2023)
7/21/2023NOTICE OF SERVICE of (1) Defendant's Responses and Objections to Plaintiff's Second Set of Interrogatories (No. 8); (2) Defendant's Responses and Objections to Plaintiff's Second Set of Requests for Production (Nos. 8-11) filed by Amgen Inc..(Hallowell, Taylor) (Entered: 07/21/2023)
7/11/2023
  • Motion to Appear Pro Hac Vice
SO ORDERED, 117 Motion for Pro Hac Vice Appearance of Attorney Rachel Williams filed by Regeneron Pharmaceuticals, Inc. Ordered by Judge Jennifer L. Hall on 7/11/2023. (ceg) (Entered: 07/11/2023)
7/11/2023
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Rachel Williams - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 07/11/2023)
7/10/2023NOTICE to Take Deposition of Thomas Moore on to be determined before July 18, 2023 filed by Regeneron Pharmaceuticals, Inc..(Wilks, David) (Entered: 07/10/2023)
7/10/2023NOTICE to Take Deposition of Adam Grennan on to be determined before July 27, 2023 filed by Regeneron Pharmaceuticals, Inc..(Wilks, David) (Entered: 07/10/2023)
7/10/2023NOTICE to Take Deposition of Kave Niksefat on to be determined before July 21, 2023 filed by Regeneron Pharmaceuticals, Inc..(Wilks, David) (Entered: 07/10/2023)
7/10/2023NOTICE to Take Deposition of Billy West on to be determined before July 12, 2023 filed by Regeneron Pharmaceuticals, Inc..(Wilks, David) (Entered: 07/10/2023)
7/5/2023NOTICE OF SERVICE of (1) Plaintiffs Third Set of Requests for Production of Documents to Defendant Amgen (Nos. 12-17), and (2) Plaintiffs Third Set of Interrogatories to Defendant Amgen No. 9 filed by Regeneron Pharmaceuticals, Inc..(Wilks, David) (Entered: 07/05/2023)
6/21/2023NOTICE OF SERVICE of Plaintiff Regeneron Pharmaceuticals, Inc. Second Set of Interrogatories to Defendant Amgen Inc. and Plaintiff Regeneron Pharmaceuticals, Inc. Second Set of Requests for Production of Documents to Defendant Amgen Inc. filed by Regeneron Pharmaceuticals, Inc..(Wilks, David) (Entered: 06/21/2023)
6/15/2023REDACTED VERSION of 107 Letter, by Amgen Inc.. (Sharp, Melanie) Modified on 6/16/2023 (nms). (Entered: 06/15/2023)
6/14/2023109
  • Order
ORAL ORDER: IT IS HEREBY ORDERED that the transcript of the June 13, 2023 discovery dispute teleconference shall serve as the Order of the Court. Ordered by Judge Jennifer L. Hall on 6/13/2023. (ceg) (Entered: 06/14/2023)
6/13/2023Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute Teleconference held on 6/13/2023. (*Court Reporter Deanna Warner.) (ceg) (Entered: 06/14/2023)
6/12/2023REDACTED VERSION of 106 Sealed Appendix B, by Regeneron Pharmaceuticals, Inc.. (Wilks, David) Modified on 6/12/2023 (nms). (Entered: 06/12/2023)
6/9/2023Pro Hac Vice Attorney Eric J. Stock for Amgen Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 06/09/2023)
6/8/2023[SEALED] Letter to the Honorable Jennifer L. Hall ,from Melanie K. Sharp, regarding discovery dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Certificate of Service)(Sharp, Melanie) Modified on 6/8/2023 (nms). (Entered: 06/08/2023)
6/5/2023[SEALED] Appendix B to 105 Letter, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Certificate of Service)(Wilks, David) Modified on 6/5/2023 (nms). (Entered: 06/05/2023)
6/5/2023CORRECTING ENTRY: The sealed exhibit filed at D.I. 106 has been removed from the docket as the filing was incompletely formatted. The filing lacked a captioned and titled cover page. Counsel is to refile the exhibit accordingly. (nms) (Entered: 06/05/2023)
6/5/2023 Letter to Honorable Jennifer L. Hall, from David E. Wilks, regarding discovery dispute. (Attachments: # 1 Proposed Order, # 2 Appendix A, # 3 Appendix C)(Wilks, David) Modified on 6/5/2023 (nms). (Entered: 06/05/2023)
6/2/2023 NOTICE of Non-Party Subpoena Duces Tecum to Elevance Health, Inc. by Amgen Inc. (Hallowell, Taylor) (Entered: 06/02/2023)
6/2/2023 NOTICE of Non-Party Subpoena Duces Tecum to CarelonRx, Inc. by Amgen Inc. (Hallowell, Taylor) (Entered: 06/02/2023)
6/1/2023 Letter to the Honorable Jennifer L. Hall, from Melanie K. Sharp, regarding status of patent case (D.I. 67 ). (Sharp, Melanie) Modified on 6/2/2023 (nms). (Entered: 06/01/2023)
6/1/2023101
  • Order
ORAL ORDER Setting Teleconference: The Court has reviewed the Amended Motion for Teleconference to Resolve Discovery Dispute (D.I. 100 ). A discovery dispute teleconference is scheduled for June 13, 2023 at 4:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than June 5, 2023, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than June 8, 2023, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Ordered by Judge Jennifer L. Hall on 6/1/2023. (ceg) (Entered: 06/01/2023)
5/25/2023
  • Motion
Amended Motion for Teleconference to Resolve Discovery Dispute - filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)Motions referred to Jennifer L. Hall.(Wilks, David) Modified on 5/26/2023 (nms). (Entered: 05/25/2023)
5/24/2023
  • Motionby Π
MOTION for Teleconference to Resolve Discovery Dispute - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Czerwonka, Scott) (Entered: 05/24/2023)
5/23/2023 NOTICE of Non-Party Subpoena Duces Tecum to The Cigna Group f/k/a Cigna Corporation by Amgen Inc. (Sharp, Melanie) (Entered: 05/23/2023)
5/23/2023 NOTICE of Non-Party Subpoena Duces Tecum to Express Scripts, Inc. by Amgen Inc. (Sharp, Melanie) (Entered: 05/23/2023)
5/23/2023 NOTICE of Non-Party Subpoena Duces Tecum to Express Scripts Senior Care Holdings, Inc. by Amgen Inc. (Sharp, Melanie) (Entered: 05/23/2023)
5/23/2023 NOTICE of Non-Party Subpoena Duces Tecum to Ascent Health Services LLC by Amgen Inc. (Sharp, Melanie) (Entered: 05/23/2023)
5/19/2023 Letter to The Honorable Jennifer L. Hall, from David E. Wilks, regarding resolution of patent case. (Attachments: # 1 Exhibit A)(Wilks, David) Modified on 5/19/2023 (nms). (Entered: 05/19/2023)
5/18/2023 NOTICE of Non-Party Subpoena Duces Tecum to Emisar Pharma Services LLC by Amgen Inc. (Sharp, Melanie) (Entered: 05/18/2023)
5/17/2023Pro Hac Vice Attorney Ashley E. Johnson for Amgen Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr) (Entered: 05/17/2023)
5/17/2023 NOTICE of Non-Party Subpoena Duces Tecum to UnitedHealthcare, Inc. by Amgen Inc. (Sharp, Melanie) (Entered: 05/17/2023)
5/17/2023 NOTICE of Non-Party Subpoena Duces Tecum to Elixir Rx Solutions of Nevada, LLC by Amgen Inc. (Sharp, Melanie) (Entered: 05/17/2023)
5/17/2023 NOTICE of Non-Party Subpoena Duces Tecum to Zinc Health Services, LLC by Amgen Inc. (Sharp, Melanie) (Entered: 05/17/2023)
5/17/2023 NOTICE of Non-Party Subpoena Duces Tecum to Prime Therapeutics, LLC by Amgen Inc. (Sharp, Melanie) (Entered: 05/17/2023)
5/17/2023 NOTICE of Non-Party Subpoena Duces Tecum to Navitus Health Solutions, LLC by Amgen Inc. (Sharp, Melanie) (Entered: 05/17/2023)
5/17/2023 NOTICE of Non-Party Subpoena Duces Tecum to Magellan Health, Inc. by Amgen Inc. (Sharp, Melanie) (Entered: 05/17/2023)
5/17/2023 NOTICE of Non-Party Subpoena Duces Tecum to Kaiser Foundation Health Plan Inc. by Amgen Inc. (Sharp, Melanie) (Entered: 05/17/2023)
5/17/2023 NOTICE of Non-Party Subpoena Duces Tecum to Humana Inc. by Amgen Inc. (Sharp, Melanie) (Entered: 05/17/2023)
5/17/2023 NOTICE of Non-Party Subpoena Duces Tecum to Dividend Group, LLC by Amgen Inc. (Sharp, Melanie) (Entered: 05/17/2023)
5/17/2023 NOTICE of Non-Party Subpoena Duces Tecum to Aetna Inc. by Amgen Inc. (Sharp, Melanie) (Entered: 05/17/2023)
5/15/2023NOTICE OF SERVICE of Third-Party Subpoena filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 05/15/2023)
5/11/2023 NOTICE of Non-Party Subpoena Duces Tecum on CaremarkPCS Health, LLC by Amgen Inc. (Sharp, Melanie) (Entered: 05/11/2023)
5/11/2023 NOTICE of Non-Party Subpoena Duces Tecum on CVS Caremark Part D Services, LLC by Amgen Inc. (Sharp, Melanie) (Entered: 05/11/2023)
5/11/2023 NOTICE of Non-Party Subpoena Duces Tecum on CVS Pharmacy, Inc. by Amgen Inc. (Sharp, Melanie) (Entered: 05/11/2023)
5/11/2023 NOTICE of Non-Party Subpoena Duces Tecum on OptumRx, Inc. by Amgen Inc. (Sharp, Melanie) (Entered: 05/11/2023)
5/1/2023NOTICE OF SERVICE of Third-Party Subpoena filed by Regeneron Pharmaceuticals, Inc..(Wilks, David) (Entered: 05/01/2023)
4/28/2023
  • Order
SO ORDERED, 72 Stipulation and Order Regarding Document Production Protocol. Signed by Judge Jennifer L. Hall on 4/28/2023. (ceg) (Entered: 04/28/2023)
4/28/2023
  • Order
SO ORDERED, 71 Stipulated Protective Order. Signed by Judge Jennifer L. Hall on 4/28/2023. (ceg) (Entered: 04/28/2023)
4/26/2023NOTICE OF SERVICE of Defendant Amgen Inc.'s Rule 26(a)(1) Disclosures filed by Amgen Inc..(Hallowell, Taylor) (Entered: 04/26/2023)
4/26/2023NOTICE OF SERVICE of Plaintiff Regeneron Pharmaceuticals, Inc. Initial Disclosures pursuant to Rule 26(a)(1)(A) filed by Regeneron Pharmaceuticals, Inc..(Wilks, David) (Entered: 04/26/2023)
4/24/2023 STIPULATION and Proposed Order Regarding Document Production Protocol by Regeneron Pharmaceuticals, Inc.. (Wilks, David) (Entered: 04/24/2023)
4/24/2023 STIPULATED Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Wilks, David) Modified on 4/24/2023 (ceg). (Entered: 04/24/2023)
4/20/2023Pro Hac Vice Attorney Adam B. Banks, Eric S. Hochstadt, Mike Moiseyev, Jonathan D. Polkes, and Elizabeth Stotland Weiswasser for Regeneron Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 04/20/2023)
4/17/2023NOTICE OF SERVICE of 6 third-party subpoenas filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 04/17/2023)
4/17/2023 NOTICE of Withdrawal of Subpoena issued to Anthem Holdings Corp. by Regeneron Pharmaceuticals, Inc. (Czerwonka, Scott) (Entered: 04/17/2023)
4/14/2023 NOTICE of Withdrawal of Pro Hac Vice Counsel, Richard G. Parker by Amgen Inc. (Hallowell, Taylor) (Entered: 04/14/2023)
4/12/2023
  • Scheduling Order
SCHEDULING ORDER: Joinder of Parties due by 8/25/2023. Amended Pleadings due by 8/25/2023. Fact Discovery completed by 12/22/2023. Expert Discovery due by 4/12/2024. Motion for Leave to File Summary Judgment Motion due by 8/31/2023. Dispositive Motions due by 5/20/2024. Answering Brief due 6/20/2024. Reply Brief due 7/12/2024. Proposed Pretrial Order due by 10/29/2024. A Pretrial Conference is set for 11/1/2024 at 08:30 AM in Courtroom 6A before Judge Richard G. Andrews. A Jury Trial is set for 11/12/2024 at 09:30 AM in Courtroom 6A before Judge Richard G. Andrews. The number of trial days will be determined at the pretrial conference. (*See Order for details). Signed by Judge Jennifer L. Hall on 4/12/2023. (ceg) (Entered: 04/12/2023)
4/11/2023 PROPOSED Scheduling Order by Regeneron Pharmaceuticals, Inc. (Wilks, David) Modified on 4/12/2023 (ceg). (Entered: 04/11/2023)
4/10/2023NOTICE OF SERVICE of (1) Plaintiff Regeneron Pharmaceuticals, Inc.s Responses and Objections to Defendant Amgen Inc.s First Set of Interrogatories (Nos. 1-2); (2) Plaintiff Regeneron Pharmaceuticals, Inc.s Responses and Objections to Defendant Amgen Inc.s First Set of Requests for Production (Nos. 1-25) filed by Regeneron Pharmaceuticals, Inc..(Wilks, David) (Entered: 04/10/2023)
4/4/2023
  • Answerby Δ
ANSWER to 1 Complaint with Jury Trial Demand by Amgen Inc..(Sharp, Melanie) (Entered: 04/04/2023)
4/4/2023Minute Entry for proceedings held before Judge Jennifer L. Hall - Telephonic Scheduling Conference held on 4/4/2023. Parties to file revised proposed scheduling order within 7 days. (*Court Reporter Stacy Ingram, Hawkins Reporting Service.) (ceg) (Entered: 04/04/2023)
3/23/2023NOTICE OF SERVICE of (1) Defendant's Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-7) and (2) Defendant's Responses and Objections to Plaintiff's First Set of Requests for Production (Nos. 1-7) filed by Amgen Inc..(Hallowell, Taylor) (Entered: 03/23/2023)
3/21/2023
  • Order
MEMORANDUM ORDER: The Objections (D.I. 54 ) are OVERRULED. The Report and Recommendation (D.I. 49 ) is ADOPTED. The motion to dismiss (D.I. 17 ) is DENIED. Signed by Judge Richard G. Andrews on 3/21/2023. (nms) (Entered: 03/21/2023)
3/16/2023NOTICE OF SERVICE of 16 Third-Party Subpoenas and Served the Subpoenas Directly on the Entities filed by Regeneron Pharmaceuticals, Inc..(Czerwonka, Scott) (Entered: 03/16/2023)
3/15/202360
  • Order
ORAL ORDER Setting Telephonic Scheduling Conference: A Scheduling Conference is scheduled for April 4, 2023 at 10:00 AM before Judge Jennifer L. Hall. The parties shall call the Court's conference line at (877) 336-1829, access code: 7090640. Ordered by Judge Jennifer L. Hall on 3/15/2023. (ceg) (Entered: 03/15/2023)
3/13/2023Joint letter to The Honorable Jennifer L. Hall, regarding Proposed Scheduling Order. (Wilks, David) (Entered: 03/13/2023)
3/13/2023PROPOSED Scheduling Order, by Regeneron Pharmaceuticals, Inc. (Wilks, David) Modified docket text on 3/14/2023 (ceg). (Entered: 03/13/2023)
3/10/2023NOTICE OF SERVICE of (1) Defendant Amgen Inc.'s First Set of Interrogatories to Plaintiff Regeneron Pharmaceuticals, Inc. and (2) Defendant Amgen Inc.'s First Set of Requests for the Production of Documents from Plaintiff Regeneron Pharmaceuticals, Inc. filed by Amgen Inc..(Hallowell, Taylor) (Entered: 03/10/2023)
3/10/2023
  • Response
RESPONSE to 54 Objections, by Regeneron Pharmaceuticals, Inc. . (Wilks, David) Modified on 3/11/2023 (nms). (Entered: 03/10/2023)
2/28/2023 Letter to the Honorable Richard G. Andrews, from Melanie K. Sharp, regarding courtesy copies. (Sharp, Melanie) Modified on 2/28/2023 (nms). (Entered: 02/28/2023)
2/24/2023OBJECTION to 49 Report and Recommendations by Amgen Inc.. (Attachments: # 1 Certification)(Sharp, Melanie) (Entered: 02/24/2023)
2/21/2023Pro Hac Vice Attorney Jessica L. Falk for Regeneron Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/21/2023)
2/21/2023
  • Motion to Appear Pro Hac Vice
SO ORDERED, 51 Motion for Pro Hac Vice Appearance of Attorney Jessica L. Falk, and 52 Motion for Pro Hac Vice Appearance of Attorney Adam B. Banks filed by Regeneron Pharmaceuticals, Inc. ORDERED by Judge Jennifer L. Hall on 2/21/2023. (ceg) (Entered: 02/21/2023)
2/17/2023 NOTICE of Withdrawal of Pro Hac Vice Counsel John Z. Ren, by Regeneron Pharmaceuticals, Inc. (Wilks, David) Modified on 2/21/2023 (nms). (Entered: 02/17/2023)
2/17/2023
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Adam B. Banks - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 02/17/2023)
2/17/2023
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Jessica L. Falk - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 02/17/2023)
2/10/202350
  • Order
ORAL ORDER: IT IS HEREBY ORDERED that, within thirty days, the parties shall jointly prepare and file a proposed Scheduling Order consistent with Judge Hall's "Rule 16 Scheduling Order - Non-Patent" up through and including paragraph number 9 (i.e., up to and including case dispositive motions) and consistent with paragraphs 8-12 of Judge Andrews' "Rule 16 Scheduling Order - Non-Patent". Thereafter, the Court may schedule a Rule 16 Scheduling Conference to be held with Judge Hall. The Scheduling Orders can be found on Judge Hall's and Judge Andrews' portions of the District Court's website. ORDERED by Judge Jennifer L. Hall on 2/10/2023. (ceg) (Entered: 02/10/2023)
2/10/2023
  • Motion to Dismiss (Demurrer)
REPORT AND RECOMMENDATION re 17 Defendant's Motion to Dismiss and ORDER denying 27 Defendant's Motion to Stay. Please note that when filing Objections pursuant to Federal Rule of Civil Procedure 72(b)(2), briefing consists solely of the Objections (no longer than ten (10) pages) and the Response to the Objections (no longer than ten (10) pages). No further briefing shall be permitted with respect to objections without leave of the Court. (Objections to R&R due by 2/24/2023). Signed by Judge Jennifer L. Hall on 2/10/2023. (ceg) (Entered: 02/10/2023)
1/6/2023Minute Entry for proceedings held before Judge Jennifer L. Hall - Motion Hearing held on 1/6/2023 re 17 Motion to Dismiss and 27 Motion to Stay filed by Amgen. The Court heard argument from the parties and took the motions under advisement (*Court Reporter Michele Rolfe.) (ceg) (Entered: 01/06/2023)
1/3/2023Remark: The in-person motion hearing scheduled for January 6, 2023 at 10:00 am before Judge Hall will take place in courtroom 2A. (ceg) (Entered: 01/03/2023)
12/7/2022 Letter to the Honorable Jennifer L. Hall, from Melanie K. Sharp, regarding procedural development (D.I. 47 ). (Sharp, Melanie) Modified on 12/8/2022 (nms). (Entered: 12/07/2022)
11/29/2022Letter to The Honorable Jennifer L. Hall, from David E. Wilks, regarding procedural development addressed in Amgen, Inc.'s letter to the Court dated November 7, 2022 (D.I. 43 ). (Wilks, David) Modified on 11/29/2022 (nms). (Entered: 11/29/2022)
11/28/2022
  • Motion to Appear Pro Hac Vice
SO ORDERED, 46 Motion for Pro Hac Vice Appearance of Attorney Jonathan D. Polkes filed by Regeneron Pharmaceuticals, Inc. ORDERED by Judge Jennifer L. Hall on 11/28/2022. (ceg) (Entered: 11/28/2022)
11/22/2022
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Jonathan D. Polkes - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 11/22/2022)
11/22/2022 NOTICE of Withdrawal of Pro Hac Vice Counsel, Gabrielle Kanter by Regeneron Pharmaceuticals, Inc. (Wilks, David) (Entered: 11/22/2022)
11/17/202244
  • Order
ORAL ORDER: At the request of counsel, the motion hearing scheduled for January 6, 2023 at 10:00 AM is converted into an in-person hearing in courtroom TBD before Judge Hall. ORDERED by Judge Jennifer L. Hall on 11/17/2022. (ceg) (Entered: 11/17/2022)
11/7/2022 Letter to The Honorable Jennifer L. Hall, from Melanie K. Sharp, regarding procedural development. (Sharp, Melanie) Modified on 11/7/2022 (ceg). (Entered: 11/07/2022)
10/26/2022REDACTED VERSION of 40 Reply Brief, by Amgen Inc.. (Hallowell, Taylor) Modified on 10/26/2022 (nms). (Entered: 10/26/2022)
10/24/2022
  • Motion to File
SO ORDERED, 39 Unopposed Motion for Leave to File Under Seal. ORDERED by Judge Jennifer L. Hall on 10/24/2022. (ceg) (Entered: 10/24/2022)
10/19/2022
  • Motion to Stay
REPLY BRIEF re 27 MOTION to Stay filed by Amgen Inc. (Sharp, Melanie) Modified on 10/19/2022 (ceg). (Entered: 10/19/2022)
10/19/2022
  • Motion to Dismiss (Demurrer)
[SEALED] REPLY BRIEF re 17 MOTION to Dismiss, filed by Amgen Inc.. (Sharp, Melanie) Modified on 10/19/2022 (nms). (Entered: 10/19/2022)
10/19/2022
  • Motion to File
UNOPPOSED Motion for Leave to File Under Seal - filed by Amgen Inc.. (Attachments: # 1 Proposed Order)Motions referred to Jennifer L. Hall.(Higgins, James) Modified on 10/19/2022 (nms). (Entered: 10/19/2022)
10/4/202238
  • Order
ORAL ORDER Setting Hearing on Motions: A hearing on the pending Motion to Dismiss (D.I. 17 ) and Motion to Stay (D.I. 27 ) is scheduled for January 6, 2023, at 10:00 AM Eastern Time via video conference before Judge Jennifer L. Hall. Each side will be allocated 30 minutes for argument. The parties shall send a joint email to Cailah_Garfinkel@ded.uscourts.gov containing the following information regarding oral argument on or before January 4, 2023: (1) a video conference link with instructions on how to join the conference; (2) a separate audio-only dial-in; and (3) a list of attendees for each party, specifying who will be presenting argument. Any video conference must be sufficient to accommodate Judge Hall, the courtroom deputy, a law clerk, and the court reporter. Any slide presentations or demonstratives that the parties wish to use during the hearing shall be emailed to Cailah_Garfinkel@ded.uscourts.gov no later than 24 hours prior to the hearing. Slide presentations or demonstratives may be presented by the parties on the video conference screen or referred to by the parties at the hearing. Once the dial-in information is received by the Court, members of the public may obtain it by contacting Chambers at Cailah_Garfinkel@ded.uscourts.gov. All participants (including any media and members of the public) are reminded that recording or broadcasting proceedings is STRICTLY PROHIBITED. All participants shall be present on the video conference no later than 10 minutes prior to the start of the hearing. ORDERED by Judge Jennifer L. Hall on 10/4/2022. (ceg) (Entered: 10/04/2022)
9/27/2022
  • Motion to FileGranted
SO ORDERED, granting 33 Unopposed Motion for Leave to File Under Seal. ORDERED by Judge Jennifer L. Hall on 9/27/2022. (ceg) (Entered: 09/27/2022)
9/26/2022REDACTED VERSION of 34 Answering Brief in Opposition by Regeneron Pharmaceuticals, Inc.. (Wilks, David) (Entered: 09/26/2022)
9/26/2022
  • Motion to Stayby Π
ANSWERING BRIEF in Opposition re 27 MOTION to Stay filed by Regeneron Pharmaceuticals, Inc..Reply Brief due date per Local Rules is 10/3/2022. (Wilks, David) (Entered: 09/26/2022)
9/26/2022 AFFIDAVIT of Eric Hochstadt re 34 Answering Brief in Opposition filed by Regeneron Pharmaceuticals, Inc.. (Wilks, David) (Entered: 09/26/2022)
9/26/2022
  • Motion to Dismiss (Demurrer)by Π
[SEALED] ANSWERING BRIEF in Opposition re 17 MOTION to Dismiss filed by Regeneron Pharmaceuticals, Inc..Reply Brief due date per Local Rules is 10/3/2022. (Attachments: # 1 Certificate of Service)(Wilks, David) (Entered: 09/26/2022)
9/23/2022
  • Motion to File
UNOPPOSED Motion for Leave to File Under Seal - filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Motions referred to Jennifer L. Hall.(Wilks, David) Modified on 9/26/2022 (nms). (Entered: 09/23/2022)
9/21/2022 NOTICE of Withdrawal of Pro Hac Vice Counsel Anthony S. Duh by Regeneron Pharmaceuticals, Inc. (Wilks, David) (Entered: 09/21/2022)
8/25/202231
  • Order
ORAL ORDER: Whereas, the parties have stipulated that briefing on the pending motion to stay will be completed on or before October 19, 2022, the Court finds good cause to delay entering a scheduling order until after that time. ORDERED by Judge Jennifer L. Hall on 8/25/2022. (ceg) (Entered: 08/25/2022)
8/25/2022
  • Order
SO ORDERED, 30 Stipulation and Order Regarding Briefing on Defendant's Motions. (*Reset Briefing Schedule re 17 Motion to Dismiss and 27 Motion to Stay: Answering Briefs due 9/26/2022; Reply Briefs due 10/19/2022). ORDERED by Judge Jennifer L. Hall on 8/25/2022. (ceg) (Entered: 08/25/2022)
8/23/2022STIPULATION and Order Regarding Briefing on Defendant's Motions, by Regeneron Pharmaceuticals, Inc.. (Wilks, David) Modified on 8/23/2022 (nms). (Entered: 08/23/2022)
8/15/2022 Letter to The Honorable Jennifer L. Hall, from David E. Wilks, regarding joint letter advising the Court on whether to enter scheduling order. (Wilks, David) Modified on 8/16/2022 (nms). (Entered: 08/15/2022)
8/11/2022 OPENING BRIEF in Support re 27 MOTION to Stay filed by Amgen Inc..Answering Brief/Response due date per Local Rules is 8/25/2022. (Sharp, Melanie) (Entered: 08/11/2022)
8/11/2022
  • Motion to Stay
MOTION to Stay - filed by Amgen Inc.. (Attachments: # 1 7.1.1. Statement, # 2 Proposed Order)Motions referred to Jennifer L. Hall.(Sharp, Melanie) Modified on 8/11/2022 (nms). (Entered: 08/11/2022)
8/8/2022REDACTED VERSION of 19 Declaration of Eric J. Stock, by Amgen Inc.. (Attachments: # 1 Exhibits A-K)(Hallowell, Taylor) Modified on 8/9/2022 (nms). (Entered: 08/08/2022)
8/8/2022REDACTED VERSION of 18 Opening Brief in Support, by Amgen Inc.. (Hallowell, Taylor) Modified on 8/9/2022 (nms). (Entered: 08/08/2022)
8/5/2022
  • Motion to Appear Pro Hac Vice
SO ORDERED, 23 Motion for Pro Hac Vice Appearance of Attorney Larry Coury filed by Regeneron Pharmaceuticals, Inc. ORDERED by Judge Jennifer L. Hall on 8/5/2022. (ceg) (Entered: 08/05/2022)
8/5/2022
  • Order
SO ORDERED, 22 Stipulation and Order regarding Temporary In-House Access to Confidential Information. Signed by Judge Jennifer L. Hall on 8/5/2022. (ceg) (Entered: 08/05/2022)
8/4/2022
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Larry Coury - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Czerwonka, Scott) (Entered: 08/04/2022)
8/3/2022
  • Motionby Δ
STIPULATION and [Proposed] Order regarding Temporary In-House Access to Confidential Information by Amgen Inc.. (Higgins, James) (Entered: 08/03/2022)
8/3/2022
  • Motion to Appear Pro Hac Vice
SO ORDERED, 21 Motion for Pro Hac Vice Appearance of Attorney Adam Bernstein and Arunabha Bhoumik filed by Regeneron Pharmaceuticals, Inc. ORDERED by Judge Jennifer L. Hall on 8/3/2022. (ceg) (Entered: 08/03/2022)
8/3/2022
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Adam Bernstein and Arunabha Bhoumik - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Czerwonka, Scott) (Entered: 08/03/2022)
8/2/2022Reset Briefing Schedule re 17 Motion to Dismiss for Failure to State a Claim: Answering Brief due 9/15/2022. Reply Brief due 10/7/2022. (See D.I. 15). (ceg) (Entered: 08/02/2022)
8/1/2022 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Amgen Inc.. (Sharp, Melanie) (Entered: 08/01/2022)
8/1/2022[SEALED] DECLARATION of Eric J. Stock re 18 Opening Brief in Support, by Amgen Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibits B-C, # 3 Exhibits D-K)(Sharp, Melanie) Modified on 8/2/2022 (nms). (Entered: 08/01/2022)
8/1/2022[SEALED] OPENING BRIEF in Support re 17 MOTION to Dismiss, filed by Amgen Inc..Answering Brief/Response due date per Local Rules is 8/15/2022. (Sharp, Melanie) Modified on 8/2/2022 (nms). (Entered: 08/01/2022)
8/1/2022
  • Motion to Dismiss (Demurrer)
MOTION to Dismiss - filed by Amgen Inc.. (Attachments: # 1 Proposed Order)Motions referred to Jennifer L. Hall.(Sharp, Melanie) Modified on 8/2/2022 (nms). (Entered: 08/01/2022)
8/1/2022
  • Motion to Appear Pro Hac Vice
SO ORDERED, 16 Motion for Pro Hac Vice Appearance of Attorney Eric Stock, Ashley Johnson, Stephen Weissman, Ben A. Sherwood and Richard G. Parker filed by Amgen Inc. ORDERED by Judge Jennifer L. Hall on 8/1/2022. (ceg) (Entered: 08/01/2022)
7/29/2022
  • Order
SO ORDERED, re 15 Stipulation filed by Amgen Inc. Signed by Judge Jennifer L. Hall on 7/29/2022. (apk) (Entered: 07/29/2022)
7/26/2022
  • Motion to Appear Pro Hac Viceby Δ
MOTION for Pro Hac Vice Appearance of Attorney Eric Stock, Ashley Johnson, Stephen Weissman, Ben A. Sherwood and Richard G. Parker - filed by Amgen Inc.. Motions referred to Jennifer L. Hall.(Sharp, Melanie) (Entered: 07/26/2022)
7/25/2022
  • Motionby Δ
STIPULATION and [Proposed] Order regarding Briefing by Amgen Inc.. (Sharp, Melanie) (Entered: 07/25/2022)
6/16/2022
  • Motion to Appear Pro Hac Vice
SO ORDERED, 7 Motion for Pro Hac Vice Appearance of Attorney Eric S. Hochstadt; 8 Motion for Pro Hac Vice Appearance of Attorney Gabrielle H. Kanter; 9 Motion for Pro Hac Vice Appearance of Attorney Anthony S. Duh; 10 Motion for Pro Hac Vice Appearance of Attorney Elizabeth Stotland Weiswasser; 11 Motion for Pro Hac Vice Appearance of Attorney John Z. Ren; 12 Motion for Pro Hac Vice Appearance of Attorney Michael R. Moiseyev; 13 Motion for Pro Hac Vice Appearance of Attorney Priyata Y. Patel; and 14 Motion for Pro Hac Vice Appearance of Attorney Robert Niles-Weed filed by Regeneron Pharmaceuticals, Inc. ORDERED by Judge Jennifer L. Hall on 6/16/2022. (ceg) (Entered: 06/16/2022)
6/16/2022
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Robert Niles-Weed - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 06/16/2022)
6/16/2022
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Priyata Y. Patel - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 06/16/2022)
6/16/2022
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Michael R. Moiseyev - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 06/16/2022)
6/16/2022
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney John Z. Ren - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 06/16/2022)
6/16/2022
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Elizabeth Stotland Weiswasser - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 06/16/2022)
6/16/2022
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Anthony S. Duh - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 06/16/2022)
6/16/2022
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Gabrielle H. Kanter - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 06/16/2022)
6/16/2022
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Eric S. Hochstadt - filed by Regeneron Pharmaceuticals, Inc.. Motions referred to Jennifer L. Hall.(Wilks, David) (Entered: 06/16/2022)
6/13/2022
  • Order
SO ORDERED, 6 Stipulated Scheduling Order Regarding Response to Complaint and Related Events. (*Reset Answer Deadlines: Amgen Inc. answer due 8/1/2022). ORDERED by Judge Jennifer L. Hall on 6/13/2022. (ceg) (Entered: 06/13/2022)
6/13/2022PROPOSED Stipulated Scheduling Order Regarding Response to Complaint and Related Events, by Regeneron Pharmaceuticals, Inc.. (Wilks, David) Modified on 6/13/2022 (nms). (Entered: 06/13/2022)
6/1/20225
  • Order
ORAL ORDER: The case is now referred to Magistrate Judge Jennifer L. Hall for all purposes through the case dispositive motion deadline. Ordered by Judge Richard G. Andrews on 6/1/2022. (nms) (Entered: 06/01/2022)
6/1/2022Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 06/01/2022)
5/31/2022 SUMMONS Returned Executed by Regeneron Pharmaceuticals, Inc.. Amgen Inc. served on 5/27/2022, answer due 6/17/2022. (Wilks, David) (Entered: 05/31/2022)
5/27/2022No Summons Issued. (twk) (Entered: 05/27/2022)
5/27/2022 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Regeneron Pharmaceuticals, Inc.. (twk) (Entered: 05/27/2022)
5/27/2022Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 05/27/2022)
5/27/2022
  • Complaint
COMPLAINT filed with Jury Demand against Amgen Inc. ( Filing fee $ 402, receipt number ADEDC-3883686.) - filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Civil Cover Sheet)(twk) (Entered: 05/27/2022)